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Abstract 
Abstract 
Schizophrenia is a lifelong disorder that affects 1% of the population worldwide and 
often begins in late adolescence or early adulthood. It is characterised by positive, 
negative and cognitive symptoms. Negative and cognitive deficits are more difficult 
to measure in rodents but may be a better predictor than positive symptoms of the 
long-term outcome following treatment of patients with schizophrenia. One of the 
major challenges in schizophrenia research is the development of suitable models 
for these aspects of the disorder. 
In this regard, one model we have studied in some detail is the 
methylazoxymethanol (MAM) neurodevelopmental model. MAM is a neuro-
specific antimitotic agent that prevents cells from dividing for a short time after 
injection. It can be administered intraperitoneally to pregnant dams on gestational 
day 17, theoretically causing neuroanatomical and behavioural alterations in 
offspring that are akin to core symptoms seen in schizophrenia. 
Our findings confirm that MAM model offspring exhibit several 
neurodevelopmental and pathological changes that bear similarities to 
schizophrenia. These include reductions in cortical thickness and hippocampal size, 
and enlargement of ventricles. Behavioural consequences of MAM, largely 
emergent after puberty, include increased locomotor responsiveness to NMDA 
antagonist administration, and also pre-pulse inhibition and cognitive flexibility 
deficits. 
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Abstract 
However, the robust neuropathological and neurophysiological findings found in 
the MAM El7 model do not always translate into behavioural deficits. This is of 
critical consequence for model validation and use in discovery research. The 
variability in behaviour effects will be discussed, taking into consideration factors 
such as litter effects, study design and statistical analysis. 
Overall, our data suggests that maternal treatment with MAM on embryonic day 17 
leads to persistent alterations in the adult offspring of so-co rats that are relevant 
for modelling aspects of schizophrenia - but revised methods for study design and 
statistical analysis are crucial to avoid misinterpretation of findings. 
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Chapter 1: General Introduction 
Chapter 1: General Introduction 
The main aims of the thesis were to investigate the validity of the MAM E17 model 
as a model for schizophrenia and to utilise the model to investigate the effects of a 
potential pro-cognitive compound in cognitive tasks to evaluate the use of the 
model as a tool for drug discovery. Therefore, this introduction will cover the 
background to schizophrenia, its treatment and how the disorder can be modelled 
in animals. 
1.1 Schizophrenia 
Modern notions of schizophrenia are mainly based on the work of two people, 
Kraepelin and Bleuler. In 1896, in the 5th edition of his Textbook of Psychiatry, Emil 
Kraepelin brought together the formerly disparate concepts of hebephrenia, 
catatonia and paranoia into a single entity that he called 'dementia praecox'. This 
name reflected his belief that its distinctive feature was mental deterioration 
usually occurring in young people. Eugen Bleuler, however, felt that the process in 
the disorders described by Kraepelin represented a splitting of psychic fu nctions 
and, in 1908, he renamed the disorder 'schizophrenia' (Black and Bofteli 1989). 
Bleuler regarded the primary symptom as cognitive dysfunction. It provided links to 
Kraepelin's 'dementia' and to the biological origins of the disease but also to 
disorders of affectivity, ambivalence, attention and will. These essential symptoms 
could be observed in every case and, according to Bleuler, schizophrenia could be 
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identified by the presence of these essential symptoms alone, while the accessory 
symptoms were not caused by the biological process or processes. These accessory 
symptoms consisted of psychotic features, such as hallucinations and delusions, 
catatonia, somatisation, changes in speech and writing, and certain mnestic 
disturbances. 
Many attempts have been made to carry forward, refine or even break up the 
syndromes described by Kraepelin and Bleuler. In the latest iteration, schizophrenia 
is thought to have three key symptom domains, positive, negative and cognitive. 
Positive symptoms are the presence of certain phenomena which are not present in 
normal individuals. These include delusions and hallucinations which can be 
auditory, olfactory, visual or even tactile (Cutting, 2003). Negative symptoms are 
described as the absence of certain functions or aspects of the mind which should 
be present in a normal individual. Common negative symptoms include anhedonia 
(lack of pleasure), apathy (diminished ability to follow through or even initiate 
plans) and alogia (reduced quantity of speech). The third category, cognitive 
impairment, includes problems in attention, learning and memory and executive 
functions such as problem solving. 
Schizophrenia typically has an age of onset between 16 and 30 years typically 
beginning with the emergence of negative and depressive symptoms, followed 
shortly by cognitive and social impairment and then the emergence of psychotic 
symptoms several years later. The whole process takes on average 5 years (Mueser 
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and McGurk, 2004). The etiology of schizophrenia is still unclear but studies suggest 
that genetics, early environment, neurobiology, psychological and social processes 
are important contributory factors and some recreational and prescription drugs 
appear to cause or worsen symptoms. There is increasing evidence suggesting that 
early insults during brain development are associated with an increased risk of 
schizophrenia (Rapoport et al., 2005). Due to the many possible combinations of 
symptoms, there is debate about whether the diagnosis represents a single 
disorder or a number of discrete syndromes. 
Although there are similar rates of incidence and prevalence of schizophrenia 
between genders, differences exist in terms of manifestation and course. Female 
patients present more affective and paranoid symptoms, whereas males show 
more negative symptoms (Lewine, 1981). Furthermore, females tend to have a 3-4-
year delay of symptom onset and first hospitalization compared with males, and a 
second peak at the onset of menopause (Hafner et al., 1993). Women also show 
better outcomes regarding social skills (Angermeyer et al., 1990) which may be 
because they have later symptom onset and are, therefore, more likely to establish 
relationships, marry, and start professional careers. Male patients tend to 
deteriorate more rapidly, especially close to symptom onset (Larsen et al., 1996). 
The most frequently confirmed neurobiological finding in schizophrenia is 
enlargement of the lateral and third ventricles which is also accompanied by overall 
reductions in brain volume and cortical grey matter (Honea et al., 2005; Zakzanis et 
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01./ 2000). The frontal lobes, amygdala, hippocampus, medial temporal lobe and 
thalamus also have decreased volumes in patients with schizophrenia compared to 
controls (Harrison and Weinberger, 2005). The ventricular enlargement and brain 
volume reductions are also present in newly diagnosed patients and occur in 
unaffected at risk relatives (Pantelis et 01./ 2007; Rapoport et 01./ 2005). 
Neuroimaging studies show structural and functional abnormalities in first-episode, 
never treated patients suggesting that these abnormalities are not secondary to 
treatment or duration of illness (Rapoport et 01./ 2005). 
1.2 Dopamine Hypothesis 
For the past 30 years, the predominant hypothesis for the pathophysiology of 
" schizophrenia has been that excessive dopamine (OA) neurotransmission in the 
forebrain contributes significantly to psychosis. It is derived from pharmacological 
evidence that OA agonists, such as amphetamine, have psychotomimetic effects 
and that the clinical potencies of anti psychotics correlate with their ability to block 
OA O2 receptors (02R) (Seeman, 2001). The consistent finding that all antipsychotic 
drugs, occupy high levels of 02 receptors, suggests that the blockade of 02 is an 
essential minimal requirement for clinical antipsychotic action in those patients 
who respond to neuroleptics (Seeman, 2001). Excessive OA transmission has also 
been supported by functional imaging studies showing that schizophrenia patients 
exhibit greater amphetamine-induced increases in synaptic OA in the striatum, 
associated with the worsening of psychotic symptoms (Laruelle et 01./ 1996). 
11 
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Although the dopamine theory of schizophrenia is supported by the correlation 
between the clinical potencies of the antipsychotic drugs and their affinity for the 
dopamine 02 receptor, there are inconsistencies that do not support the theory. 
While antipsychotic drugs can often control the positive symptoms of 
schizophrenia, such as hallucinations and delusions in the acute setting, the same 
antipsychotics tend to be less effective in patients who have been symptomatic for 
many years. It is also true, however, that many schizophrenia patients may not 
clinically improve despite high occupancy (>75%) of their 02 receptors (Seeman, 
2001). In addition, the antipsychotics are much less effective at addressing negative 
symptoms or the cognitive impairments, after a year of treatment which coincides 
with the emergence of reduction of PFC volume (Paz et 0/., 2008). There has also 
been little evidence of dopamine receptor abnormality in schizophrenia. Post-
'mortem studies initially suggested that there could be an increased density of 
striatal dopamine 02 receptors in schizophrenia (Owen et 0/., 1978; Mackay et 0/., 
1980a; Seeman et 0/., 1984), but there has been controversy as to whether these 
results arose as a result of chronic antipsychotic treatment (Clow et 0/., 1980; 
Mackay et 0/., 1980b). Studies using single photon emission tomography and 
positron emission tomography methods in drug naive patients with schizophrenia 
have also failed to find any difference in dopamine 02 receptor density in vivo 
compared to controls (Farde et 0/., 1990; Martinot et 0/., 1991; Pilowsky et 0/., 
1994). A recent meta-analyses (Laruelle, 1998; Zakzanis and Hansen, 1998) 
suggested that there may be a small elevation in dopamine 02 receptors in drug-
free patients with schizophrenia; however; the degree of overlap between patients 
12 
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and controls makes it unlikely that this abnormality is clinically meaningful (Zakzanis 
and Hansen, 1998). 
1.3 Glutamate Hypothesis 
The N-methyl-D-aspartic acid (NMDA) receptor hypofunction (Glutamate) 
hypothesis of schizophrenia was developed in part to explain some of these 
inconsistencies. Glutamate is the major excitatory neurotransmitter in the central 
nervous system. Its receptors are classified into two broad categories: ionotropic 
and metabotropic receptors. lonotropic glutamate receptors (iGlu), which include 
NMDA, kainate, and AMPA subtypes, initiate rapid depolarization by facilitating 
sodium or calcium entry into neurons through channels formed by the receptor 
itself. Metabotropic glutamate receptors (mGlu) modulate neurotransmission by 
activating G-protein coupled synaptic transduction mechanisms. Some mGlu 
receptors, in particular the mGluS subtype, interact closely with NMDA receptors 
and may directly modulate the function of the NMDA receptor channel. Executive 
functions of the prefrontal cortex, including working memory and behavioural 
flexibility are impaired by NMDA antagonists and are therefore thought to be 
critically dependent on NMDA receptors (Verma and Moghaddam, 1996; Dalton et 
01., 2011; Featherstone et 01., 2012). They also play an essential role in the 
development of neural pathways, particularly for neuronal migration during brain 
development, making them a critical component of developmental processes 
(Haberny et 01., 2002). 
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The idea of a glutamatergic abnormality in schizophrenia was first proposed by Kim, 
Kornhauber, and colleagues in 1980 (Kim et aI., 1980) based on their findings of low 
cerebrospinal fluid (CSF) glutamate levels in patients with schizophrenia, however 
these findings could not be replicated at the time. In the last two decades, 
however, basic and clinical evidence has been accumulating to support the idea 
that aberrant NMDA receptor function subserves many aspects of molecular, 
cellular, and behavioural abnormalities associated with schizophrenia. Clinical 
observations of abusers of the NMDA receptor antagonist phencyclidine (PCP) 
showed that PCP exposure resulted in disordered thought and confusion, emotional 
blunting, auditory hallucinations, impulsiveness and working memory deficits (Javitt 
and Zukin., 1991; Luby et al., 1959). Ketamine another NMDA receptor antagonist, 
also induces a clinical state similar to schizophrenia including both positive and 
negative symptoms, and can worsen symptoms in clinically stable patients (Jentsch 
and Roth., 1999) further supporting the theory. PCP and Ketamine can also lead to 
cognitive deficits as shown by impaired performance in the Wisconsin Card Sort and 
Vigilance tasks and it has also been shown that the pro-psychotic effects of 
phencyclidine and ketamine can be effectively treated by haloperidol (Giannini et 
al., 2000). Other behavioural studies show that hyperlocomotion and working 
memory impairments induced by PCP are correlated with increased glutamate 
levels in the PFC (Adams and Moghaddam., 1998) and microdialysis studies have 
shown that glutamate levels are increased in the striatum (Bustos et al., 1992) and 
PFC (Moghaddam et al., 1997) of animals acutely treated with NMDA antagonists. 
14 
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Simply stated, the hypothesis proposes that NMDA receptor hypofunction, the 
condition induced by an NMDA antagonist, might also be viewed as a model for a 
disease mechanism which could explain the symptoms and natural course of 
schizophrenia. Several lines of evidence have also suggested that a typical 
consequence of NMDAR hypofunction is reduced glutamatergic excitation of 
subcortical gamma-amino-butyric acid (GABA) interneurons, which results in 
disinhibition of glutamate (as well as dopamine and acetylcholine) 
neurotransmission to the cortex (Homayoun and Moghaddam., 2007; Krystal et al., 
2003; Moghaddam, 2003). In addition, increased glutamate signalling mainly at 
AMPA receptors has also been found to be a possible downstream effect of NMDAR 
blockade (Moghaddam and Javitt 2011; Moghaddam et al., 1997]. It has been 
proposed that this excessive release of excitatory transmitters and consequent 
overstimulation of postsynaptic neurons might explain the cognitive and 
behavioural disturbances associated with schizophrenia (Olney and Farber, 1995, 
Moghaddam et aI., 1997 and Adams and Moghaddam, 1998). Hence, refinements 
of the glutamate hypothesis postulate that behavioural and cognitive symptoms of 
schizophrenia appear to be caused by a dysregulation of glutamatergic 
neurotransmission, characterised by NMDAR hypofunction and subsequent excess 
glutamatergic activity. 
In schizophrenic patients, postmortem studies have shown changes in glutamate 
receptor binding and subunit protein expression in the prefrontal cortex, thalamus, 
and hippocampus (Akbarian et al., 1996, Clinton and Meador-Woodruff., 2004) and 
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significant reductions in NMOA receptor binding have also been found in 
medication-free, but not antipsychotic-treated schizophrenic patients compared to 
healthy subjects (Pilowsky et 01., 2006). Levels of amino acids N-acethylaspartate 
(NAA) and N-acethylaspartylglutamate (NAAG), and the activity of the enzyme that 
cleaves NAA to NAAG and glutamate are also altered in the CSF and postmortem 
tissue from individuals with schizophrenia (Tsai et aI., 1995). NAAG is an 
endogenous ligand for the mGlu3 subtype of glutamate receptor, the gene for 
which has been implicated in increased propensity to develop schizophrenia. 
Furthermore, reduced NAA levels are thought to reflect decreased glutamate 
availability. 
Glutamate neurons regulate the function of other neurons that have been strongly 
implicated in the pathophysiology of schizophrenia. These include GABA 
interneurons whose morphology has been altered in schizophrenia (Lewis et aI., 
2005), and dopamine neurons, which are the target of antipsychotic drugs. For 
example, bursting of dopamine neurons, which is thought to be an integral 
\ 
component of their proper response to environmental stimuli, is dependent on 
activation of NMOA receptors on these neurons (Johnson et aI., 1992). Along the 
same lines, it is noteworthy that two key pharmacological clues to the 
pathophysiology of schizophrenia-clinical efficacy of 02 receptor antagonist and 
increased probability of developing schizophrenia after cannabis use during 
adolescence-are consistent with deficient NMOA receptor function in 
schizophrenia. Cannabinoid CB1 receptor and 02 receptors are localized 
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presynaptically on glutamate terminals and work to inhibit the release of 
glutamate. Cannabis, therefore, reduces glutamate release, in particular in 
corticostriatal regions (Gerdeman and Lovinger, 2001), leading to deficient 
activation of NMDA receptors, whereas reduced D2 receptor function produces 
modest increases in glutamate release (Cepeda et aI., 2001; Yamamoto and Davy, 
1992). 
These lines of evidence have led to the current thinking that disruptions in any of 
the numerous mechanisms that influence the function of NMDA receptors, by 
either modifying the kinetics of the NMDA channel itself, or the function of proteins 
that link NMDA receptors to signal transduction pathways, can compromise 
behaviour in a manner suggested by the symptoms of schizophrenia. This theory is 
consistent with the complex genetic predisposition feature of schizophrenia 
because it predicts that any of the genes that encode or regulate the large number 
of proteins that influence the function of NMDA receptors would be plausible 
sl,!sceptibility genes for this disease. In addition to theoretical implications, these 
fin9ings have been the basis for identification of novel therapeutic targets for 
.. 
treatment of schizophrenia (Moghaddam and Adams, 1998). A recent proof-of-
concept clinical trial paper by Eli Lilly shows promising results with one of these 
compounds (Patil et aI., 2007). This double-blind placebo-controlled study showed 
that after four weeks of treatment, an agonist for the metabotropic glutamate 2/3 
receptor (mGlu2/3R) has similar efficacy as olanzapine in ameliorating positive and 
negative symptoms of schizophrenia .. 
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Several approaches have been made in recent years to integrate the evidence for 
glutamatergic abnormalities and dopamine in the pathogenesis and current 
treatment of schizophrenia (Stone et 01./ 2007; Javitt 2007; Laurelle et 01./ 2003). A 
current, widely supported theory states that dopaminergic imbalances in striatal 
and cortical areas are preceded and modulated by NMDAR hypofunction in the PFC. 
In turn, the arising dopaminergic dysregulation might further disrupt glutamatergic 
signalling at NMDA receptors (Stone 2011; Laurelle et 01./ 2003; Toda and Abi-
Dargham., 2007). Dopaminergic dysregulation might therefore be the result of 
impairments of glutamate neurotransmission and a subsequent reinforcing factor in 
maintaining these impairments (Coyle., 2006). In fact, lower glutamate levels in 
hippocampal areas of individuals in the prodromal states of schizophrenia, but not 
in healthy controls, have been found to be linked to increased dopaminergic 
neurotransmission (Stone et 01./ 2010). 
Glutamatergic theories of schizophrenia account for negative symptoms and 
c9,gnitive dysfunction, as well as positive symptoms, and thus may lead to new 
trefltment approaches specifically targeting this unmet medical need. Improving the 
.. 
future treatment of schizophrenia and increasing our biological understanding of 
the disease will be contingent on development of appropriate models and 
biomarkers for glutamatergic drug development. Although clinical drug 
development progresses slowly, the field has now progressed to the point where 
treatment predictions of the glutamate model can be tested. 
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1.4 Neurodevelopmental Hypotheses 
The emergence of psychosis several years after early structural brain changes led to 
the hypothesis that schizophrenia is a neurodevelopmental disorder. The 
hypothesis states that schizophrenia, or a predisposition to the disease, results 
from pre- and/or peri-natal disturbances that affect normal CNS development 
(Harrison., 1997). As previously mentioned, structural changes are apparent before 
first-episode and in first-degree relatives indicating that the abnormalities are a 
expression of familial risk factors, the most likely being genes affecting 
neurodevelopment. Further evidence that neuropathological changes in 
schizophrenia are prenatal rather than postnatal comes from the absence of glial 
reactions in the brains of schizophrenics. Glial reactions (gliosis) are a reactive 
cellular process that occurs after injury to the CNS. As with scarring in other organs 
and tissues, the glial scar is the body's mechanism to protect and begin the healing 
process in the nervous system. The process of gliosis involves a series of cellular and 
molecular events that occur over several days (Fawcett et aI., 1999). Typically, the 
first response to injury is the migration of macrophages and local microglia to the 
injury site. This process, 'which constitutes a form of gliosis known as microgliosis, 
begins within hours of the initial CNS injury. 3-5 days later, oligodendrocyte 
precursor cells are also recruited to the site and may contribute to remyelination. 
The final component of gliosis is astrogliosis, the proliferation of surrounding 
astrocytes, which are the main constituents of the glial scar (Fawcett et aI., 1999). 
Gliosis is common to most adult-onset br@ininjuries and neurodegenerative 
disorders such as Alzheimer's disease but not with neuropathological events 
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occurring in early development. Furthermore, post-mortem histological studies 
have shown cortical cytoarchitectural abnormalities which can only occur during 
early brain development. Findings in this area indicate defective cellular 
organisation where the laminar distribution of cortical neurons is displaced 
inwards. The normal migration of neurons intended for cerebral cortex proceeds 
outwards during the second trimester of gestation; a defect in the cortical layers of 
schizophrenics suggests a defect in the neuronal migration during this 
developmental stage. These findings are particularly important because they are 
difficult to interpret in other than neurodevelopmental terms (Weinberger., 1995). 
It has long been recognised that schizophrenia is highly familial suggesting a 
possible genetic aetiology. Lifetime risk to siblings of schizophrenic patients is about 
ten times the population risk and using twin data a heritability of 0.6-0.S has been 
estimated (Owen et al.,2000). It is generally accepted that there are multiple 
susceptibility genes and according to two recent meta-analyses, approximately 12 
r e ~ i o n s s of the genome are now thought to contain schizophrenia susceptibility 
gen.es (Badner and Gershon., 2002; Lewis et al 2003). These genes include dysbindin 
.. 
(6p22), neuregulin 1 (Sp12), G72 (13q34), RGS4 (regulator of G protein Signalling 4) 
(lq21, q22), COMT (catechol-o-methyltransferase (22qll) and DISC 1 (disrupted in 
schizophrenia 1) (lq42). It is thought that the different genes may have differential 
relevance at different stages of development and under different environmental 
conditions and, therefore, interact with each other as well as with environmental 
risk factors to produce the clinical con.dition. 
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Many groups have now examined prenatal exposure to influenza as a candidate risk 
factor for schizophrenia. Maternal exposure to viral infection has been associated 
with an increased risk of schizophrenia, and it has been suggested that the maternal 
immune response may interfere with normal foetal brain development. A study 
suggested that foetuses exposed during the second trimester to the 1957 type A2 
influenza pandemic have an increased risk of schizophrenia (Mednick et al., 1988). 
Those exposed to the viral epidemic during their second trimester of foetal 
development were at elevated risk of being admitted to a psychiatric hospital with 
a diagnosis of schizophrenia. This was true for both males and females and 
independently in several psychiatric hospitals. The second-trimester effect was 
seen in the elevated proportion of schizophrenics among those admitted to a 
psychiatric hospital and also in higher rates of schizophrenia per 1000 live births in 
the city of Helsinki (Mednick et al., 1988). Another group identified that a 
population of males who, as foetuses, were exposed to the 1969 Hong Kong 
influenza epidemic had a significantly elevated schizotypal personality scores 
c o ~ p a r e d d to controls. Further analysis revealed that these differences were 
accQunted for by those exposed to the influenza virus in week 23 of the gestation 
"" 
cycle (Machon et al., 2001). Although studies in rodents have shown that perinatal 
viral infections can lead to neuropathological and behavioural abnormalities 
considered relevant to schizophrenia (Fruntes and Limosin., 2008; Romero et al., 
2008), it is not clear whether the consequences of prenatal infection are due to the 
infection itself or to the maternal immune response to infection. One theory is that 
the maternal cytokine-associated inflammatory response to infection may be a 
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crucial link as the identity of the pathogen seems to be irrelevant (Romero et al., ~ ~
2008). Maternal serum levels of the cytokine tumour necrosis factor-a or 
interleukin are elevated in mothers of patients with schizophrenia. In addition to 
their immunological roles, cytokines have been shown to affect survival, 
differentiation and morphology of developing neural cells. Therefore, variations in 
the levels of inflammatory cytokines in the foetal environment may therefore 
adversely affect the development of the nervous system and contribute to the 
development of future psychobehavioural and/or cognitive impairment (Romero et 
al./2008). 
There has also been considerable interest in recent years of the impact of prenatal 
malnutrition. Susser et al., (1996) identified an increased risk of schizophrenia in 
the offspring of women who were pregnant during a famine in Holland during 
World War II. The risk of schizoid personality disorder, as defined by ICD-6 to ICD-9, 
in men at age 18 years was compared in birth cohorts that were conceived during 
t h ~ ~ Dutch Hunger Winter famine and in unexposed birth cohorts. The exposed 
coh9rt had a significantly greater risk of schizoid personality disorder (Hoek et al., 
1996). Another group assessed the effects of nutritional deficiency during the first 
trimester of pregnancy on brain morphology in patients with schizophrenia exposed 
during the first trimester of gestation to the Dutch Hunger Winter. Prenatal famine 
exposure in patients with schizophrenia was associated with decreased intracranial 
volume and an increase in brain abnormalities, predominantly white matter hyper-
intensities in controls (Hulshoff et al., 2000). 
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Low prenatal vitamin D has also been proposed as a candidate for a risk factor for 
schizophrenia (McGrath., 1999). In a review by Bouillon et af., (1995), evidence was 
presented linking vitamin D with cell growth and proliferation, immune response 
and foetal development. It has been shown to be a potent inducer of nerve growth 
factor synthesis but the precise links between vitamin D and the central nervous 
system are still poorly understood. One of the most robust findings in schizophrenia 
epidemiology is that a high percentage of patients with schizophrenia are born in 
winter. Moskovitz (1978) suggested that the marked seasonal variations in the 
serum level of vitamin D may be linked to the seasonality of schizophrenia births. 
Low vitamin D levels are frequently reported during winter and more vitamin D is 
required during pregnancy due to the rapid growth of the foetus, especially in the 
third trimester. It is therefore hypothesised that the high number of winter births 
seen in schizophrenia may be related to low maternal vitamin D levels associated 
with reduced light during the winter period (McGrath., 1999). 
The most extensively studied of early developmental markers are obstetric 
'.') 
complications (OCs). Many obstetric risk factors have been linked with 
"-
schizophrenia including pre-eclampsia (Kendell et af., 1996), low birth weight (Jones 
et af., 1998), rhesus factor incompatibility (Hollister et af., 1996) and maternal 
bleeding during pregnancy (Hultman et af., 1999). It has been reported that the 
relative risk for schizophrenia was increased up to 2.5 times by pre-eclampsia, 
gestational age below 33 weeks, respiratory illness and low birth weight. Pre-
eclampsia, an indicator of foetal malnutrition emerged as the strongest risk factor, 
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increasing the risk for schizophrenia between 2 and 2.5 times (Dalman et al., 1999). 
Sacker et al., (1995) found that schizophrenia was associated with a higher 
likelihood of risk behaviour during pregnancy by the mothers, including smoking, 
drinking and poor prenatal care but these behaviours do not qualify as DCs and 
therefore are not used in most studies. 
1.5 Treatment of Schizophrenia 
Current antipsychotics are divided into typical (e.g haloperidol and chlorpromazine) 
and atypical (e.g. clozapine, olanzapine and risperidone) groups based on their 
affinity for dopaminergic receptors (Meltzer et al., 1989). Both classes of drug act 
on the dopaminergic system with more or less affinity toward D2 receptors. The 
typical antipsychotics are effective in reducing positive but not negative symptoms 
of psychosis but also have several side effects due to chronic blockade of D2 
receptors in the striatum. The newer atypical antipsychotic drugs are usually 
preferred for initial treatment as they are often better tolerated and associated 
with lower extrapyramidal side effects as well being more effective in reducing the 
negative and cognitive symptoms. However they are also more likely to induce 
weight gain and obesity related diseases (olanzapine) (Liberman et al., 2005) or 
agranulocytosis (clozapine) (Haas et al., 2007). Due to the large number of 
antipsychotics available, many have not been compared head to head until 
recently. Leucht et al (2013) however performed a multiple-treatment meta-
analysis to compare the efficacy and tolerability of 15 different antipsychotic drugs 
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in schizophrenia. They compared two first generation antipsychotics (haloperidol 
and chlorpromazine) with 13 second generation antipsychotic drugs. They found 
that Clozapine was the top-ranking antipsychotic in terms of efficacy (figure 1) with 
amisulpride, olanzaoine and risperidone also more effective than the rest of the 
drugs. However, Leucht et al emphasise that the differences in efficacy between 
drugs were small (standardised mean differences 0·11-0·55, median 0·24), but, for 
perspective, the efficacy differences compared with placebo were of only medium 
size (0·33-0·88, median 0·44), so the differences in efficacy between drugs are 
possibly substantial enough to be clinically important. Also, because most clozapine 
studies were done in refractory patients, clozapine is thought to be superior only in 
this subtype, but in our analysis of non-refractory patients it was also more 
effective than all the other drugs. However, this result has the limitation that it was 
mainly based on older comparisons of clozapine with first-generation drugs. There 
was no clear winner in terms of side effects (all cause discontinuation, 
extrapyramidal side-effects, prolactin increase, OTc prolongation and sedation) 
w i t ~ ~ the differences among drugs being much larger than the changes observed for 
effic?lcy (Leucht et aI., 2103). 
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Overall change in symptoms 
dozapine-O·88 (-1·03 to-O-73) I • 
Amisulpride-O·66 (-0·78 to-0·53) 
Olanzapine-0'59 (-0·65 to-O'53) 
Risperidone-O'56 (-0·63 to-O'50) 
Paliperidone -0·50 (-0·60 to -0·39) 
Zotepine -0·49 (-0·66 to -0·31) 
Haloperidol-O'45 (-0,51 to-0-39) 
Quetiapine -0·44 (-0'52 to -0-35) 
Aripiprazole -0·43 (-0,52 to-O· 34) 
Sertindole-O·39 (-0·52 to-O·26) 
Ziprasidone-O'39 (-0·49 to-O·30) 
Chlorpromazine-O'38 (-0·54 to-O·23) 
Asenapine-0·38 (-0·51 to-O-25) 
lurasiclone-0'33 (-0·45 to-O·21) 
lloperidone -0·33 (-0·43 to-0·22) 
-1 
+-
Favours active drug 
o 
Figure 1: Forest plot for efficacy of antipsychotics drugs compared with placebo 
(leucht et al 2013) 
Treatments are ranked according to their surface under the cumulative ranking 
(SUCRA) values (appendix p 98).5MO=standardised mean difference. Crl=credible 
interval. 
It is not clear which neurobiological mechanisms beyond 02 receptor antagonism is 
the final therapeutic target responsible for the beneficial effects seen in 
schi·zophrenia. Many of the atypical antipsychotics have been further characterised 
with" respect to their affinities for different receptors (table 1) (Horacek et al., 
2006). The hypothetical mechanisms of action of atypical antipsychotics can be 
classified into dopaminergic, sertonergic or combined modulation effects. 
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Table 1: Pharmacodynamic characteristics and classification of selected 
antipsychotics and clinical criteria characterising atypical anti psychotics (Horacek et 
al., 2006) 
As previously mentioned, 02 receptor blockade in the brain is a general 
pharmacodynamics' property of all antipsychotics, and without it, a drug will not 
show any antipsychotic properties (Seeman, 2002). With typical antipsychotics, the 
level of 02 blockade is directly related to the antipsychotic effect, but this is not the 
case with atypicals. It has also repeatedly been confirmed that 02 receptor 
occupancies >80% are associated with extra-pyramidal side effects (EPS) (Farde et 
. al., 1988; Farde et al., 1992; Goyer et al., 1996; Kapur et al., 1999). The substituted 
benzamines antipsycotics (table 1), for example, remoxipride and amisulpride, have 
a higher affinity for 03 than 02 receptors (Scatton et al., 1997). 03 receptors are 
localised in the limbic cortex, therefore, blocking these receptors would result in 
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regionally selective anti-dopaminergic activity, resulting in an accentuated effect on 
positive symptoms (Bressan et al., 2003; Leucht et al., 2002). 
Partial agonism of D2 receptors is another model for explaining the properties of 
atypical anti psychotics. Partial agonism is when binding to the receptor, the drug, 
blocks the effects of the extracellular physiologically active substance (e.g. 
dopamine) but at the same time has an agonistic effect on the receptor. 
Aripiprazole is an example of an antipsychotic which uses this model. This partial 
agonism results in high D2 occupancy at therapeutic doses with low EPS (Burris et 
al., 2002). 
Interest in serotonergic modulation for the treatment of schizophrenia arose from 
the finding that SHT2A receptor agonists (e.g. LSD) are strong psychedelic drugs that 
can elicit psychotic symptoms. SHT2A receptors are localised on hippocampal and 
cortical pyramidal cells, as well as on GABA neurons. The highest density of 
r e c ~ p t o r s s is in the fifth neocortex layer where the inputs of various cortical and 
subcortical brain areas are integrated (Willins et al., 1997; Jacob et al., 1998). As 
SHT2A agonism induces depolarisation of pyramidal cells, it has been speculated 
that SHT2A blockade is responsible for normalisation of pyramidal cell activity which 
leads to the therapeutic activity of atypical antipsychotics (Martin et al., 1998). 
Some atypicals (clozapine and risperidone) and some typicals (e.g. chlorpromazine, 
fluphenazine) have high affinities for S-HT2C receptors. SHT2C receptors have been 
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found in cortical areas and in the hippocampus, striatum, septal, thalamic and 
midbrain nuceli and brain stem. In cortical areas, these receptors appear to be 
mostly expressed on glutamatergic pyramidal cells and it has been suggested that 
that they control monoaminergic and cholinergic neurons. In the substantia nigra, 
5-HT2c receptors are co-localised with GABA, indicating that they yield indirect 
control of dopaminergic transmission (Leyson, 2004). The blockade of 5ht2c 
receptors on GABA cells in the substantia nigra would potentiate 02 receptor 
mediated tonic inhibitory control with a protective effect against EPS (Oi Matteo et 
01.,2001). 
Agonism of 5HT1A receptors is also considered a possible mechanism associated 
with the activity of some atypical antipsychotics (aripiprazole, clozaline, qutiapine, 
risperidone) (Meltzer et 01.,2003). 5HT1A receptor blockade prevents the increase in 
dopamine in the prefrontal cortex induced by these drugs, even with olanzapine 
which does not express 5HT1A receptor affinity (Ichikawa et 01., 2001). Generally it 
m a ~ { { be concluded that a simple effect at serotonergic receptors is probably not 
sufficient for an antipsyhotic effect in schizophrenia but that it works in 
combination with O2 receptor blockade. 
Meltzer et 01., (1989) defined atypical antipsychotics drugs as those showing a 
higher affinity for 5-HT2A receptors than for 02 receptors and a lower affinity for O2 
receptors than that seen ~ i t h h typical antipsychotics. For the nigrostriatal pathway, 
a model has been suggested in which blockade of SHT2A receptors leads to 
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increased output of dopaminergic neurones into the striatum. Such. increased 
extracellular activity of dopamine in the striatum displaces the antipsychotic from 
its binding to 02 receptors and thus decreases the risk of EPS development (Kapur 
and Remington, 1996). SHT2Ai02 receptor antagonism on the mesolimbic 
dopaminergic pathway into the nucleus accumbems is linked with greater efficacy 
against the positive symptoms of schizophrenia (Van, 2000; Pehak et 01., 2001). On 
dopaminergic mesocortical projections, SHT 2A receptor antagonism increases 
dopamine release in the prefrontal cortex. This effect is thought to be linked with 
antipsychotic effects on cognitive and negative symptoms (Seeman, 1994; Ichikawa 
and, Meltzer., 1990). 
Some atypicals, such as olanzapine and clozapine, have a marked affinity for 
cholinergic muscarinic (M1 and M4) receptors. These are predominantly expressed 
in the frontal and limbic areas of the brain (Levey, 1993; Bymaster et 01., 2003). The 
main effect of antimuscarinics is to antagonise antipsychoticOinduced EPS, and the 
affinity of antipsychotics for muscarinic receptors has been shown to be inversely 
correlated with EPS effects (Snyder et aI., 1974). 
Taking into consideration the side effect problems with current treatments, it is 
necessary to look for new psychotropic drugs which have a better efficacy, a faster 
onset of action and fewer adverse side effects. As altered glutamate neuronal 
transmission has been suggested to be important in the etiology of schizophrenia, 
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drugs which target metabotropic glutamate receptors and enhance NMDA function 
may be alternative efficacious antipsychotics. 
MGlu2 and mGlu3 receptors are highly localized within limbic and forebrain areas 
associated with schizophrenia including the hippocampus, and prefrontal cortex 
(Ohishi et al. 1993a and b) and in recent years, several lines of evidence have shown 
that mGlu2/3 receptor agonists may be effective for the treatment of schizophrenia 
in both animal models and in humans. mGlu2/3 receptor agonists have been 
reported to attenuate locomotor hyperactivity induced by an NMDA receptor 
antagonist (Moghaddam and Adams., 1998, Rorick-Kehn et al., 2007) and 
amphetamine (Rorick-Kehn et al., 2007, Galici et al., 2005) in rodents. Moreover, 
mGlu2/3 receptor agonists have also been shown to inhibit conditioned avoidance 
responding (Rorick-Kehn et al., 2007, Takamori et al., 2003] and reverse the effects 
of stress and anxiolytic-like and antipsychotic-like effects in a variety of preclinical 
rodent in vivo paradigms including fear- potentiated startle in rats and marble 
burying in mice (Rorick-Kehn et al., 2007). LY354740, an mGlu2/3 agonist, improved 
PCP-impaired performance in a T-maze discrete-trial delayed alternation task 
(Moghaddam and Adams., 1998) and reversed the deficits of social discrimination 
induced by neonatal treatment with PCP (Harich et al., 2007). Decreased levels of 
glutamate and changes in several markers of glutamatergic function also occur in 
schizophrenic brain. As previously mentioned, administration of PCP or ketamine to 
rodents elicits an increase in locomotion and stereotypy, this is also accompanied 
by an increase in glutamate efflux in several brain regions. Systemic administration 
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of mGlu2/3 receptor agonists suppresses PCP-induced behavioural effects and the 
increase in glutamate efflux. Thus, drugs such as mGlu2/3 receptor agonists which 
might correct or normalize glutamatergic functions may have therapeutic promise 
in treating schizophrenia. 
mGlus receptor agonists have been reported to attenuate PCP, ketamine, 
amphetamine, and apomorphine induced increases in locomotor hyperactivity 
(Chan et al., 2008, Kinney et al., 2005, Liu et al., 2008), improve PPI disruption and 
object recognition memory impairment induced by ketamine (Chan et al., 2008) 
and to reduce conditioned avoidance responding in rats (Liu et al., 2008). These 
findings suggest that mGlus receptor potentiation exerts antipsychotic activity in 
animal models and may be effective for the positive symptoms of schizophrenia. In 
a novel object recognition test, mGlus recpetor agonists have also improved the 
impaired recognition capability that was induced by MK-801 or ketamine (Liu et al., 
2008, Uslaner et al., 2009) and attenuated MK-801-impaired task performance in a 
set-'shifting paradigm (Darrah et al., 2008). They have also been found to enhanced 
object recognition memory in a novel object recognition test (Liu et al., 2008) and 
spatial memory in Ymaze spatial alternation (Balschun et al., 2006) and Morris 
water maze task (Ayala et al., 2009), indicating that mGlus receptor potentiators 
may have memory-enhancing effects, even for normal conditions. Therefore, 
enhancement of mGlus receptor activity with mGlus receptor potentiators may be 
effective for treating the dysfunctions of several cognitive domains associated with 
schizophrenia. The involvement of the mGlus receptor on cognition is further 
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supported by a study of mGluS receptor-null mice. These mice exhibited reduced 
long-term potentiation in the CAl region and dentate gyrus of the hippocampus 
(NMDA receptor dependent pathways), but not in the CA3 region (an NMDA 
receptor-independent pathway). mGluS receptor-null mice also displayed impaired 
spatial learning in a Morris water maze task, impaired contextual learning during 
fear-conditioning (Lu et 01., 1997) and disrupted PPI (Kinney et 01., 2003). 
1.6 Modelling schizophrenia in animals 
Despite fifty years of drug development research, one of the biggest challenges in 
schizophrenia-related drug discovery is to find an appropriate animal model of the 
illness so that novel hypotheses can be tested at the basic science level. As more 
knowledge of the pathophysiology of schizophrenia accrues, it is essential that 
appropriate animal models of the illness be developed that have better 
translational value. A number of pharmacological, genetic, and 
(" 
neurodevelopmental models have been introduced; however, none of these 
.. 
models has been rigorously evaluated for translational relevance or to satisfy 
requirements of "face," "construct" and "predictive" validity. Figure 2 shows a 
diagram of the key behavioural, neurochemical and structural changes expected be 
present, and to have translational relevance to the three core symptom domains of 
schizophrenia, in an animal model of the disorder (Jones et 01., 2011): The degree of 
phenomenological similarity between the animal model and the human condition it 
is meant to simulate is known as face validity. In the context of schizophrenia, 
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challenges to face validity immediately arise due to the nature of the symptoms of 
the illness. For examples, some features of schizophrenia are uniquely human 
(language disorders) and others (hallucinations, delusions) are impossible to 
determine in animals. However, several symptoms known to have an important 
impact on illness outcome in schizophrenia can be modelled successfully in animals. 
These include deficits of information processing (e.g., prepulse inhibition) and 
several domains of cognition (e.g., attention, working memory). Other symptoms 
that can be modelled successfully in animals include hyperactivity, sensitivity to 
psychostimulants, and deficits in latent inhibition. The level of homology between 
the animal model and the human illness that underlies disease symptoms is known 
as construct validity. Demonstrating construct validity for animal models of 
schizophrenia is difficult since neither the underlying neurobiological substrates of 
the behavioural symptoms nor the cognitive deficits have been clearly established. 
However, several animal models exhibit some pathophysiological features that 
have been detected in schizophrenia (e.g., neurotransmitter deficits, enlarged 
ventricles, decreased hippocampal volume). Predictive validity in drug discovery is 
prim'arily defined by the degree to which the model can be used to predict efficacy 
of a new therapeutic agent in humans. Typically, in drug discovery research, 
assessing the effects of positive-control compounds provides this type of validation. 
In schizophrenia, positive controls for some of the symptoms of schizophrenia (e.g., 
efficacy in prepulse inhibition, impairment models, amphetamine locomotor assays) 
have been identified but this has been more difficult for the negative and cognitive 
symptoms. Given the apparent polygenic nature of schizophrenia and the limited 
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translational significance of pharmacological models, neurodevelopmental models 
may offer the best chance of success. 
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Figure 2: Schematic diagram of the key behavioural, neurochemical and structural 
changes expected be present and to have translational relevance to the three core 
symptom domains of schizophrenia in an animal model of the disorder. (Jones et 
01., 2011) 
Many approaches have been taken to represent schizophrenia in animals including 
pharmacological, i.e.; perinatal PCP and neonatal ventral hippocampal lesions, 
genet ic via knock-out mice and neurodevelopmental, which include social isolation 
and disruption of neurogenesis using immune activation or the antimitotic 
Methylazoxymethanol Acetate (MAM). Table 2 shows a table from Jones et aI., 
(2011) comparing different animal models of schizophrenia, however this 
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introduction will concentrate on models that target the glutamatergic system and 
the hippocampus. 
NMDA receptor antagonists such as phencyclidine (PCP) and ketamine mimic a ' 
range of schizophrenia symptoms including positive and negative symptoms as well 
as thought disorder in normal humans and can elicit a prolonged reoccurrence of 
the acute psychotic state in patients with stable chronic schizophrenia (Javitt and 
Zukin., 1991). PCP was administered on post natal days (PND) 7, 9 and 11 (10mg/kg) 
and as neurodevelopment is still occurring during this time (figure 3) it is 
hypothesised that apoptosis caused by PCP treatment would result in deficits in 
function directly or indirectly under cortical control. The perinatal PCP exposure 
resulted in long lasting deficits in sensorimotor gating, spatial learning and 
sensitisation to PCP-induced hyperlocomotor activity, furthermore, these effects 
are blocked by the atypical antipsychotic, olanzapine (Wang et al., 2001). 
<I 
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Table 2: Comparative overview of the changes in basal and psychostimulant-induced locomotor activity in an open-field arena; sensorimotor 
gating; learning and memory; social interaction with a conspecific, structural and neurochemical changes in cortical and hippocampal areas 
and the reversal of these changes with antipsychotic and related drugs for selected animal models of schizophrenia . (Jones et al., 2011) 
Gestational MAM Spontaneous Deficit in PPI appears Normal acquisition, but Reduced total social Reduced PFc and 
(G017) hyperactivity in novel at puberty. impaired re-Ieaming in interaction appears hippocampal size, enlarged reversal of behaviour 
(Moore et a/., 2006; arena emerging at the prior to puberty. ventricals, reduced attempted. CLZ does 
Lodge et a/., 2009) puberty. Enhanced Morris water maze; hippocampal soma size and not reverse change in 
amphetamine- and impaired extra- neuropil; enhanced nAcc DA BDNF. 
NMDA antagonist- dimensional release; spontaneously 
induced shift in attentional set- hyperactive VT A DA 
locomotion. shifting task neurones; decreased PFc 
Parvalbumin GABA 
interneurones 
Post-weaning social Hyperactivity in a novel Persistent, but strain- Deficit in novel object Increased aggression Reduced PFc volume; PPI reve 
isolation arena appearing 2-3 dependent reduction in recognition; no effect on and increase in total reduced dendritic spine anti psychotics, 02 
(Lapiz et al. , 2003; Fone weeks after commencing PPI to acoustic startle acquisition of spatial social Interaction density, cytoskeletal antagonists, a7-nicotinic 
and Porkess, 2008) isolation; hyper- appearing about 6 weeks learning by impaired alteration and loss of agonists; novel object 
responsivity to after isolation reversal learning in water parvalbumin-containing discrimination 
amphetamine and maze, extradimensional interneurones and reelin in impairment reversed by 
cocaine together with shift in the attentional the hippocampus; reduced 5-HT6 antagonists and 
increased nAcc DA set-shifting task and fear- PFc 01 binding, no change mGluR2/3 agonist 
release motivated conditioned in striatal 02 density, but 
emotional response increased proportion of 
striatal 02 High; increased 
spontaneously active VT A 
DA neurones 
Amphetamine Sensitization of Persistent deficit in PPI Deficits in attention and No reduction in social Enhanced mesolimbic DA Locomotor sensitization 
models locomotor response to dependent on dosage the attentional set- interaction response; altered Ach blocked by CLZ and 
(Featherstone et a/., amphetamine regimen shifting task; function in PFc HLP; moderate 
2007a; Featherstone et hippocampal- dependent attenuation of attention 
a/., 2008; Sarter et a/., memory unimpaired impairment by CLZ and 
009) HLP 
PCP models Sensitization of No sustained deficit in Deficits in novel object Reduced frequency Reduced basal and stress- Deficits in reversal 
(Jentsch and Roth, locomotor response to PPI recognition, attentional and duration of induced PFc DA and learning reversed by 
1999; Phillips et al., PCP; hyper-responsive set primate social glutamate release; atypical antipsychotics 
2001; Mouri et al., 2007; locomotor response to shifting and T-maze behaviour decreased synaptic spines but not HLP; locomotor 
Neill et al. , 2010) amphetamine and mild delayed alternation on Fc neurones and cortical sensitization attenuated 
stress and hippocampal by CLZ and HLP 
parvalbumin-positive 
neurones 
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Neonatal ventral Locomotor hyper- Adult onset deficit in PPI Impaired acquisition of T- Deficits in social Unaltered basal nAcc DA Amphetamine-induced 
hippocampal responsivity to stress, maze delayed alternation interaction with release, but enhanced hyperactivity reversed 
lesion amphetamine and NMDA and water maze; increased response to stress or by acute or chronic 
(Lipska, 2004; Tseng et receptor antagonists; impaired radial arm maze aggression at all amphetamine; reduced antipsychotic injection; 
al., 2009) enhanced apomorphine- c choice accuracy; developmental ages mPFc NAA levels and social interaction deficit 
induced stereotypy selective deficit in extra- GAD6? mRNA expression not 
dimensional shift and reversed by CLZ 
reversal in the attentional 
set-shifting task 
DISC-1 knock-out Hyperactivity seen in Deficits in PPI seen in Impaired T-maze Reductions in social Reduced brain volume in PPI deficits in L 1 OOP 
(Jaaro-Peled, 2009) L100P, CaMK-DC some (e.g. constitutive performance seen in activity seen in some most strains; enlarged mice reversed by HLP 
mutants, but not in CaMK-DC, L100P, most strains; impaired strains (e.g. 031 L) lateral ventricles, reduced and CLZ 
others; no data available 031 L), but not all spatial working memory and some CaMK- DC hippocampal and PFc 
regarding mutants (e.g. inducible only seen in female transgenics dendritic density, structure 
psychostimulant-induced CaMK-DC, D25 bp); PPI CaMK-DC inducible and complexity in some 
locomotor activity to date not tested in CaMK cc or mutants strains; reduced 
BAC DC mutants hippocampal parvalbumin 
immunoreactivity in some, 
but not all mutants 
Neuregulin1 and Most, but not all, PPI deficits seen in most Impaired contextual fear Some deficits in Increased lateral ventricles Spontaneous and 
ErbB4 knock-out neuregulin and ErbB4 neuregulin mutants and mismatched social interaction, and reduced hippocampal psychostimulant induced 
(Harrison and Law, mutants show reviewed; ErbB4 mutants negativity increased aggression spine density; reduction in Locomotor hyperactivity 
2006a; Mei and spontaneous locomotor show normal PPI performance in some and reduced functional forebrain NMDA reversed by CLZ in 
Xiong, 2008) hyperactivity, but mutants responses to social receptors Nrg1(DTM)+I- and 
inconsistent responses novelty Nrg1 (BACE)-I- mutants 
to psychostimulants 
Dysbindin knock-out Spontaneous locomotor Increased PPI and startle Increased acquisition of Reduced social Hyperexcitability of PFc No data on antipsychotic 
(Karlsgodt et al. , hyperactivity and hyper- response shown to be T-maze task; impaired contact during social pyramidal neurones; altered reversal 
2011; Papaleo responsivity to reversed by quinpirole, spatial reference memory interaction synaptic structure 
et al. , 2010) amphetamine challenge but not eticlopride and novel object task and formation; elevated 
recognition performance HV AIDA ratio in cortico-
limbic regions 
Reelin knock-out Reduced locomotion in Variable PPI responses, Few memory deficits Some modulation of Increased neuronal packing Normalization of reduced 
(Krueger et al., an open field; enhanced highly dependent on reported; normal reversal social activity in and decreased dendritic spontaneous activity by 
2006; Tueting response to strain, learning and inhibitory novelty andlor spine density in PFc and OLZ 
et al., 2006) methamphetamine environment and testing control, normal MWM interaction tasks hippocampal neurones 
protocol performance; some 
leaming deficits in 
acquisition of operant 
tasks 
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The neonatal ventral hippocampal lesion (NVHL) model reproduces several 
behavioural abnormalities observed in schizophrenia, including hypersensitivity to 
stimulants, hyperactivity, reduced social interactions, and impaired working 
memory (Lipska and Weinberger., 2000). In this model, ibotenic acid is infused 
directly into rat ventral hippocampus on PND· 7 which leads to a number of 
dopamine related behaviours that resemble behaviour seen in animals sensitised to 
psychostimulants. Chronic Clozapine and Risperidone treatment reverse the 
locomotor hyperactivity and PPI deficits, but not social interaction deficits seen, in 
this model (Rueter et al., 2004). However this model lacks construct validity as 
schizophrenia brains do not manifest a lesion analogous to the ventral hippocampal 
lesion in this model. 
(\ 
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E17 (Adapted from Bayer et al. 1993) 
Figure 3: Timeline of brain development from conception to PND20. 
Conception = GDO and birth = PNDl. 
Metnylazoxymethanol (MAM) is a neurospecific antimitotic agent that prevents 
cells from dividing for a short time after injection (8alduini et 01., 1991; Cattabeni 
and Luca., 1997). Injection on embryonic day 17 (E17) is therefore likely to have a 
major impact on the brain structures that are actively developing at this time (see 
figure 3), including the cortical areas, hippocampus and limbic system which have 
been shown to be deficit in function in schizophrenia patients (Liddle at al 2006). 
MAM-E17 exposure also leads to a pattern of histopathology similar to that 
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observed in schizophrenia and behavioural abnormalities with translational 
homology to dysfunction of the frontal cortex and limbic and dopaminergic inputs 
to striatum (Moore et 01., 2006). Specifically it has been shown to reduce the 
thickness of the hippocampus, thalamus and several cortical regions as well 
decreases in total brain weight of about 11% (Flagsted et 01., 2004). Previous 
studies show that adult offspring of MAM E17 treated rats have enhanced 
sensitivity to MK-801 (Le Pen et 01., 2006) and amphetamine (Moore et 01., 2006) 
induced hyperlocomotion and deficits in prepulse inhibition which are not seen in 
pre-pubescent rats (Le Pen et 01., 2006). PCP induced orofacial dyskinesia, thought 
to be an index of frontocortical lesions, was also enhanced in these offspring 
(Moore et 01./ 2006). Several studies have also shown cognitive deficits in these 
offspring. In a spatial working memory paradigm, the alternating V-maze, MAM E17 
rats learnt the initial rule quicker than the controls but too longer to learn the rule 
reversal (Moore et 01./ 2006). In a radial arm maze task, MAM E17 rats were again 
able to learn the tas.k but were impaired in the spatial working memory component 
(Gourevitch et 01., 2004). In the attentional set-shifting bowl digging task, MAM E17 
rats n took significantly more trials to reach criterion in the reversal and extra-
" 
dimensional shift trials (Featherstone et 01./ 2007, Gastambide et 01./ 2012). MAM 
E17 injected rats may therefore be an important neurodevelopmental model for 
schizophrenia. 
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1.7 Measuring changes in animal models of· 
schizophrenia 
Because of the complexity of schizophrenia the approach to the development of 
animal models relies on focusing on specific phenotypic signs or symptoms 
associated with the disorder rather than mimicking the entire syndrome. By 
focusing on specific signs and symptoms rather than the syndrome it increases the 
confidence in the cross species validity of the model. Here specific observations 
.. 
that have been identified in schizophrenic patients provide a focus for study and 
therefore the validation of any model can only be as sound as the information 
available in the relevant clinical literature. Another approach is based more on 
theoretically on psychological constructs believed to be affected in schizophrenia. 
These include attention, perseveration, sensorimotor gating and working memory. 
Behavioural measures have been used extensively for establishing the validity of 
animal models in schizophrenia. Hyperlocomotion is used primarily as a functional 
{\ 
measure of dopaminergic activity in response to neuroleptics but antagonism of 
.. 
locomotor activity is thought to be comparable with the positivE:! symptoms of 
schizophrenia.·· Other behavioural measures, such as disruption of prepulse 
inhibition of acoustic startle or impaired attentional set shifting also resemble 
.. 
. characteristics of schizophrenia. These measures are useful for establishing the 
constnj·ct and predictive validity of putative animal models (Willner., 1986). 
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Changes in locomotor activity in rodents have often been used to assess both 
models of schizophrenia and the effects of antipsychotic treatments. Cross species 
studies in animals treated with psychostimulants show hyperlocomotor activity and 
at higher doses stereotypic and perseverative behaviours which are thought to 
have face validity with the stereotyped behaviours induced by amphetamine, PCP 
and ketamine in humans. 
Clinical observations in schizophrenic patients have also identified deficiencies in 
.. the processing of information including inability to filter or 'gate' irrelevant 
thoughts and sensory stimuli. Numerous studies have observed deficits in the 
habituation of startle responses in schizophrenic patients which may reflect failures 
of sensory filtering leading to disorders of cognition. Prepulse inhibition (PPI) is a 
test of pre-attentional sensorimotor gating and is based on the fact that a weak 
prestimulus presented 30-50 milliseconds before a startling stimulus reduces or 
'gates' the amplitude of the startle response (Geyer and Swerdlow., 1998). This 
phenomenon is robust, is observed in many species and is evident both within and 
between multiple sensory modalities when a variety of stimulus parameters are 
" 
used. These stimulus-evoked changes in PPI are similar in humans and rats, and DA 
agonists, such as apomorphine, and NMDA antagonists such as PCP disrupt PPI in 
both species, so mimicking the PPI deficits observed in patients with schizophrenia. 
The administration of antipsychotic drugs can also restore this psycho stimulant 
induced PPI deficit (Geyer et al., 2001). 
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Cognitive deficits are reported across all subtypes of schizophrenia. including 
impairments of working memory, attention, verbal memory and set shifting. The 
limited cognitive capacity of rodents hinders the development of cognitive tasks 
that can be considered to be entirely analogous to human tasks such as the 
Wisconsin Card Sorting Task and Continuous Performance Test. Some common 
rodent cognitive assays, such as delayed matching to position, delayed alternation, 
fear conditioning, reversal learning and the five choice serial reaction time task 
have been developed to look at specific aspects of learning and memory and it is 
important to utilise a battery of such tasks when evaluating any new animal model 
of the disorder. 
1.8 Aims of the thesis 
This thesis aims to investigate the validity of the MAM E17 model as a model for 
schizophrenia. 
(\ 
The first aim was to characterise the model in different strains of rats and to also 
assess any potential sex and age effects. This initially involved establishing the 
MAM E17 pup generation protocol within the institution. A battery of tests was 
used to measure different aspects of behaviour: locomotor activity and prepulse 
inhibition of acoustic startle. 
The second aim was to assess the effect of MAM treatment on cognition using an 
operant reversal learning'task and a fear c o n d i t ~ o n i n g g task and to examine whether 
any deficits could be reversed using a potentially cognition enhancing compound. 
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2.1 Introduction 
The aetiology of schizophrenia is still unclear but studies suggest that genetics, early 
environment, neurobiological and psychological processes are all important 
contributory factors (Rapoport et al., 2005). There are similar rates of incidence and 
prevalence of schizophrenia between genders, however differences exist in terms 
of manifestation and course. Female patients present more affective and paranoid 
symptoms, whereas males show more negative symptoms (Lewine., 1981). 
Furthermore, females tend to have a 3-4-year delay of symptom onset and first 
hospitalization compared with males, and a second peak at the onset of menopause 
(Hafner et al., 1993; Maurer et al., 1993), thus any animal model needs to include 
sex comparisons. 
{\ 
Preschizophrenic individuals exhibit minor deviations in motor, cognitive, and social 
development, suggesting that abnormalities in brain function are present very early 
in life in individuals who later develop schizophrenia (Rapoport et al., 2005). 
Consistent with this, post-mortem studies have revealed reduced volume, 
. decreased neuronal size, and a loss and/or mal positioning of cells in the 
hippocampus and prefr<?ntal, entorhinal and cingulate cortices of schizophrenic 
patients (Harrison and Weinberger., 2805). 
45 
Chapter 2: Validation 
As mentioned in the previous chapter Methylazoxymethanol (MAM), when given 
on embryonic day 17 (MAM E17), it leads to a pattern of histopathology similar to 
that observed in schizophrenia, namely reduced thickness of the hippocampus, 
thalamus and several cortical regions as well decreases in total brain weight of 
about 11% (Flagstad et 0/.,2004). 
Only a basic assessment of MAM in behaviour has been researched so far, and the 
aim of the studies was to firstly establish the model on site and then to further 
.. behaviourally characterise the model. A strain comparison will be performed as 
there is no literature on the MAM model in Lister Hooded rats and there are 
literature reports of strain differences in behavioural tasks. Weiss et 0/., (2000) 
investigated the effects of isolation rearing on acoustic startle response, PPI and 
locomotor activity in Sprague Dawley (SO) and Lister Hooded (LH) rats and showed 
that LH rats had rncreased locomotor activity compared to the SO strain and less 
sensitivity to apomorphine in PPI. Another laboratory looked at the effect of dosing 
(\ 
LH and SO rats daily with nicotine and then microdialysis studies were performed 
., 
on day . ~ ~ with a challenge dose of nicotine of 0.4 mgjkg. SO rats pre-treated with 
nicotine showed increased basal overflow of OA in the accumbal core and pre-
treatment with 0.1 and 0.3mgjkg also resulted in sensitisation of the response to a 
0.4 mg/kg nicotine challenge. In LH rats, pre-treatment with nicotine reduced basal 
overflow in the accumbal core and did not cause sensitisation to a subsequent 
challenge with nicotine (Iyaniwura et 0/., 2001). Mirza and Bright (2001) tested LH 
and CD rats in the SCSRT task and their responses to nicotine. CD rats only reached 
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an accuracy of approximately 60% whereas LH rats reached 80%. Higher doses of 
nicotine improved the accuracy in the task in SO rats but not the LH rats. 
We also performed sex comparison of MAM treatment since the age of onset and 
symptoms of schizophrenia depends on gender, and all previous MAM studies 
exposure have been on male pups. Animal neurochemical data shows there are sex 
differences in central dopamine levels (Castner et 01., 1993) as well as sensitivity to 
amphetamine (Beatty and Holtzer., 1978). Male rats also seem to be affected to a 
... greater extent by neonatal ventral hippocampal lesions than females. In tests of 
social interaction, the number of encounters were significantly decreased in female 
lesioned rats whereas male lesioned rats showed a significantly reduced duration of 
active social interactions. Furthermore, a deficit of spatial learning and memory was 
only shown in male lesioned rats in the Morris Water Maze test rats {Silva-Gomez 
2003}. 
{\ 
The effects of dosing MAM on E15 as well as E17 was also be examined in the 
n 
current .. project. Prenatal .exposure to MAM at E15 affects primarily telencephalic 
(endbrain) areas such as cortex and hippocampus. Treatment at this time also leads 
to gross motor impairments, including ataxia and a blunted startle reflex. A marked 
impairment .in rule learning, reversal learning and passive avoidance tasks is 
observed in these rats {Moore et 01., 2006; Balduini et 01., 1991}. MAM treatment at 
E15 was therefore used as a positive control. 
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The effect of MAM treatment on locomotor activity, prepulse inhibition of the 
acoustic startle response and brain and body weight was measured together with 
the effect of MK-801 on locomotor activity. 
{\ 
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2.2 Methods 
2.2.1 Experiment 1: Strain Comparison in 
Methylazoxymethanol Acetate (MAM) treated animals 
.. 
2.2.1a Subjects 
Twenty four timed-pregnant Sprague Dawley (Crl:CO(SO)) (SO) and Lister Hooded 
(Crl:LlS) (LH) dams, were obtained from Charles River, Margate, UK on El0 and 
randomly split into 4 groups. Each group was treated with either MAM or saline 
(SHAM group) on either embryonic day 15 (E15) or day 17 (E17). 4 days after birth 
the litters were culled to 10, keeping equal numbers of males and females where 
possible and only those litters born on E22 were kept. On postnatal day 28 the pups 
t\ 
w e ~ ~ ~ weaned and re-housed in groups of 3 or 4 with non-littermates of the same 
strain, sex and treatment. The cages of rats were then randomly assigned to two 
groups, juvenile (tables 1 and 2) and adult (tables 4 and 5) and those animals tested 
at juvenile age were not retested at adulthood. The timeline for testing is depicted 
. in figure 1 and the n numbers are in shown in table 3 . 
.. 
All experiments were conducted in full compliance with the Home Office Guidance 
(Animals (Scientific Procedures) Act 1986, project licence 70/6560) and the ethical 
policies of Eli L i l l y ~ ~ Facilities were also AAALAC (Association for Assessment and 
49 
.. 
Chapter 2: Validation 
Accreditation of Laboratory Animal Care) accredited. Housing rooms were 
temperature-controlled (21± 10 C) and maintained on a 12: 12 h light/dark cycle 
(lights on at 07:00). Food and water were available ad libitum. 
Day 1 21 34 83 
Birth Weaning Juvenile Adult 
I I 
Juvenile PPI and LMA Adult PPI AdultLMA Adult brain 
brain weights 
Figure 1: Timeline of events and studies performed for Experiment 1: Strain 
Comparison in Methylazoxymethanol Acetate (MAM) treated animals 
2.2.1b Drugs 
Methylazoxymethanol acetate (MAM) was obtained from Midwest Research 
Institute (Kansas City, Missouri, http://www.mriresearch.org) and was administered 
intraperitoneally (Lp.) at a dose of 28 mg/kg, expressed as salt weight. MAM was 
dissolved in 0.9% saline and administered in a volume of 1 ml/kg. MAM is light 
sensitive and was stored, formulated and maintained in light-restricting bottles . 
. \
M K ~ 8 0 1 1 Maleate (Sigma Aldrich, UK) was administered subcutaneously (s.c.) at a 
dose of 0.1 mg/kg, as base, in 5% glucose in a volume 1 mg/ml. 
2.2.1c Neuroanatomy 
2.2.1c(i) Brain weights and Tissue 
Animals were terminally anaesthetised using isoflurane and then trans-cardially 
perfused with 0.9% saline followed by 10% buffered formalin. The brain was 
50 
Chapter 2: Validation 
removed and stored in the 10% buffered formalin and weighed 24hrs·later. The 
brains were then placed on clean absorbent tissue and photographs taken. 
Perfused brains were kept in formalin before being cut into segments using an ASI 
Rodent Brain Matrix Coronal RBM-8000C (pup matrix) for the juvenile samples and 
ASI Rodent Brain Matrix Coronal RBM-4000C (adult matrix) Bilaney Consultants Ltd, 
UK). The juvenile brains were cut into two segments (forebrain and hindbrain) and 
the adult brains cut into 3 segments (bregma 6.12 to bregma -1.32mm, bregma -
1.32 mm to bregma -6.84 mm and bregma -6.84 mm to bregma - 13.20 mm) and 
... 
placed in mega-cassettes (Medim, UK) of the TISSUE-TEK VIP2000 vacuum 
infiltration processor (Miles Scientific, Bayer Diagnostics, UK) and processed 
overnight (see (O'Neill and Clemens 2001). Brain segments were then embedded in 
blocks of paraffin wax for subsequent histopathology. Coronal sections ( 8 ~ m ) ) were 
taken from bregma 6.12mm to bregma -9.96 mm. A second cohort of brains were 
processed using multibrain technology (NeuroScience Associates (NSA), Knoxville, 
TN, USA, www.neuroscienceassociates.com) and 4 0 ~ m m sections cut using a freezing 
(\ 
microtome. 
2.2.1c(ii) Neuropathology and image analysis 
Sections from selected stereotaxic levels throughout the brain were stained with 
cresyl violet using an X-V Varistainer (ThermoShandon, UK). On completion of 
staining the slides were cover slipped with Consul-mouneM using an automated 
Shandon Consul® coverslipper (Therr:noShandon, Cheshire, UK). The slides were 
cleaned and the samples from the first study were scanned using SprintScan 3S 
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hardware (model CS2700, Polaroid) and the images analysed using Optimus 5.2 
software. For all subsequent studies, slides were scanned using Aperio Scanscope 
XT hardware and digital images generated using ImageScope software (Ape rio 
Technologies Inc.). To confirm the key pathological changes in the MAM tissues, the 
areas of the medial prefrontal cortex (mPFC) at bregma 4.68mm, the dorsal 
hippocampus at bregma -3.12 and the lateral ventricles at bregma -4.08 was 
calculated by tracing around the structure and compared to the area of the same 
structure in SHAM treated rats . 
Table 1: Detail of CD Sprague Dawley pups tested in PPI, LMA and used for 
histology at the juvenile timepoint for Experiment 1: Strain Comparison in 
Methylazoxymethanol Acetate (MAM) treated animals. 
CD 
Pup Group Sex Cage Pup 10 Group Sex Cage 10 
E276 MAME15 Male 1 C263 MAM E17 Female 30 
K340 MAM E15 Male 1 F292 MAM E17 Female 30 
P381 MAM E15 Male 1 S412 MAME17 Female 30 
0389 MAM E15 Male 1 X467 MAME17 Female 30 
8245 MAM E15 Male 10 0272 MAME17 Female 32 
{\ K339 MAM E15 Male 10 M358 MAM E17 Female 32 
L350 MAM E15 Male 10 U435 MAM E17 Female 32 
T420 MAM E15 Male 10 X464 MAM E17 Female 32 
8252 MAM E15 Female 12 H308 SHAM E17 Male 54 
K342 MAM E15 Female 12 1316 SHAM E17 Male 54 
P387 MAM E15 Female 12 R400 SHAM E17 Male 54 
0394 MAM E15 Female 12 W450 SHAM E17 Male 54 
E279 MAM E15 Female 15 H309 SHAM E17 Female 57 
L353 MAME15 Female 15 1320 SHAM E17 Female 57 
0392 MAM E15 Female 15 R406 SHAME17 Female 57 
T427 MAME15 Female 15 W455 SHAME17 Female 57 
C257 MAME17 Male 23 A234 SHAM E15 Male 41 
F284 MAM E17 Male 23 G297 SHAM E15 Male . 41 
N362 MAME17 Male 23 J327 SHAME15 Male 41 
U429 MAM E17 Male 23 V441 SHAM E15 Male 41 
0264 MAM E17 Male 26 A243 SHAM E15 Female 49 
F289 MAM E17 Male 26. G303 SHAM E15 Female 49 
N364 MAM E17 Male 26 J332 SHAM E15 Female 49 
X458 MAM E17 Male 26 V446 SHAME15 Female 49 
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Table 2: Detail of Lister hooded pups tested in PPI, LMA and used for histology at 
the juvenile timepoint for Experiment 1: Strain Comparison in 
Methylazoxymethanol Acetate (MAM) treated animals. 
LH 
Pup Group Sex Cage Pup Group Sex Cage ID ID 
C19 MAME15 Male 2 F45 MAM E17 Female 33 
D28 MAM E15 Male 2 179 MAME17 Female 33 
G55 MAM E15 Male 2 M115 MAME17 Female 33 
P144 MAM E15 Male 2 0141 MAME17 Female 33 
A3 MAME15 Male 7 F49 MAME17 Female 35 
E38 MAM E15 Male 7 H69 MAME17 Female 35 
L106 MAME15 Male 7 M118 MAME17 Female 35 
X220 MAME15 Male 7 V209 MAM E17 Female 35 
D30 MAME15 Female 10 K94 SHAME15 Male 41 
L107 MAME15 Female 10 N123 SHAME15 Male 41 
P148 MAME15 Female 10 S175 SHAM E15 Male 41 
C26 MAME15 Female 10 U191 SHAME15 Male 41 
D34 MAME15 Female 13 K99 SHAME15 Female 46 
G61 MAME15 Female 13 N131 SHAM E15 Female 46 
X223 MAME15 Female 13 S177 SHAME15 Female 46 
A7 MAM E15 Female 13 U198 SHAME15 Female 46 
813 MAM E17 Male 18 J85 SHAM E17 Male 50 
173 MAM E17 Male 18 0153 SHAM E17 Male 50 
0134 MAM E17 Male 18 W210 SHAME17 Male 50 
T184 MAM E17 Male 18 R163 SHAM E17 Male 50 
89 MAM E17 Male 21 J89 SHAME17 Female 59 
172 MAME17 Male 21 0156 SHAME17 Female 59 
M114 MAM E17 Male 21 R169 SHAME17 Female 59 
V204 MAME17 Male 21 W216 SHAM E17 Female 59 
Table 3: n numbers for Experiment 1: Strain Comparison in Methylazoxymethanol 
Acetate (MAM) treated animals. 
" CD LH 
.. PPI LOCO PPI LOCO 
Group Sex Adult Adult Juvenile Adult Juvenile Vehicle MK-801 
" Adult Adult Juvenile Adult Juvenile Vehicle MK-801 
E15 MAM Male 8 16 - 8 8 8 8 16 8 8 8 
E15 MAM Female 8 16 8 8 8 8 16 8 8 8 
E17 MAM Male 8 16 8 8 8 8 16 8 8 8 
E17 MAM Female 8 16 8 8 8 8 16 8 8 8 
E15 SHAM Male 4 12 4 6 6 4 12 4 6 6 
E15 SHAM Female 4 12 4 6 6 4 12 4 6 6 
E17 SHAM Male 4 12 4 6· 6 4 12- 4 6 6 
E17 SHAM Female 4 12 4 6 6 4 12 4 6 6 
48 112 48 56 56 48 112 48 56 56 
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Table 4: Detail of CD Sprague Dawley pups tested in PPI, LMA and used for histology 
at the adult timepoint for Experiment 1: Strain Comparison in 
Methylazoxymethanol Acetate (MAM) treated animals. 
CD 
Pup 10 Group Sex Cage Pup Group Sex Cage Pup 10 Group Sex Cage ID 
B249 MAM E15 Male 2 C260 MAME17 Female 33 A241 SHAM E15 Female 47 
L346 MAME15 Male 2 N365 MAM E17 Female 33 G299 SHAM E15 Female 47 
P378 MAME15 Male 2 S415 MAME17 Female 33 J330 SHAM E15 Female 47 
T422 MAME15 Male 2 U437 MAME17 Female 33 V443 SHAME15 Female 47 
K335 MAME15 Male 4 0273 MAM E17 Female 34 G298 SHAME15 Female 48 
K338 MAM E15 Male 4 M357 MAM E17 Female 34 G300 SHAM E15 Female 48 
0388 MAM E15 Male 4 S414 MAM E17 Female 34 48 
0390 MAME15 Male 4 U436 MAM E17 Female 34 48 
B247 MAM E15 Male 5 0270 MAME17 Female 36 1318 SHAM E17 Male 50 
K336 MAME15 Male 5 F291 MAM E17 Female 36 R399 SHAM E17 Male 50 
P380 MAM E15 Male 5 U433 MAME17 Female 36 50 
T421 MAME15 Male 5 X463 MAM E17 Female 36 50 
E274 MAM E15 Male 6 D269 MAM E17 Female 38 R402 SHAM E17 Male 51 
L347 MAM E15 Male 6 M359 MAM E17 Female 38 W451 SHAME17 Male 51 
P379 MAME15 Male 6 U432 MAME17 Female 38 51 
0391 MAM E15 Male 6 X465 MAME17 Female 38 51 
E277 MAME15 Female 13 E282 MAME15 Female 17 H304 SHAM E17 Male 52 
K341 MAM E15 Female 13 0373 MAM E15 Female 17 1315 SHAM E17 Male 52 
P386 MAM E15 Female 13 P382 MAM E15 Female 17 R398 SHAM E17 Male 52 
T423 MAME15 Female 13 0395 MAM E15 Female 17 W449 SHAME17 Male 52 
E281 MAM E15 Female 14 A239 SHAM E15 Male 40 H305 SHAM E17 Male 53 
L352 MAM E15 Female 14 J328 SHAM E15 Male 40 1317 SHAM E17 Male 53 
0376 MAME15 Female 14 V440 SHAME15 Male 40 R401 SHAM E17 Male 53 
T426 MAM E15 Female 14 40 W448 SHAM E17 Male 53 
8253 MAM E15 Female 16 A236 SHAME15 Male 42 H310 SHAME17 Female 55 
E280 MAM E15 Female 16 G295 SHAM E15 Male 42 R403 SHAM E17 Female 55 
0374 MAME15 Female 16 J326 SHAME15 Male 42 55 
0396 MAM E15 Female 16 V438 SHAME15 Male 42 55 
Q266 MAM E17 Male 22 A237 SHAM E15 Male 43 1319 SHAME17 Female 56 
F287 MAME17 Male 22 G296 SHAM E15 Male 43 R404 SHAM E17 Female 56 
S410 MAM E17 Male 22 43 56 
X460 MAME17 Male 22 43 56 
C254 MAM E17 Male 24' A235 SHAM E15 Male 44 H311 SHAM E17 Female 58 
F285 MAM E17 Male 24 G294 SHAM E15 Male 44 1322 SHAM E17 Female 58 
S411 MAM E17 Male 24 J325 SHAM E15 Male 44 R405 SHAM E17 Female 58 
U428 MAME17 Male 24 44 W456 SHAM E17 Female 58 
D267 MAM E17 Male 27 A242 SHAME15 Female 45 H313 SHAME17 Female 59 
M354 MAM E17 Male 27 G302 SHAM E15 Female 45 1321 SHAM E17 Female 59 
N360 MAM E17 Male 27 45 W452 SHAME17 Female 59 
X461 MAM E17 Male 27 45 R407 SHAM E17 Female 59 
0265 MAM E17 Male 29 A240 SHAM E15 Female 46 
-- ... ----.-- r -.------._------ .. 1- . -----.-. ~ ~
M355 MAM E17 Male 29 G301 SHAM E15 Female 46 
-•.. ,., 
.. - , - ~ - - - - - - - ~ ~ - ---.-.' .-'.-.. -
S408 MAME17 Male 29 J333 SHAME15 Female 46 I 
, 
. ' ~ ~ .---.. -_._--.- --- .. -_."-
U430 MAM E17 Male 29 V447 SHAM E15 Female 46 I 
_ .. -.. - .. " ~ - . . , '. ~ - . ~ ~
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Table 5: Detail of Lister Hooded pups tested in PPI, LMA and used for histology at 
the adult timepoint for Experiment 1: Strain Comparison in Methylazoxymethanol 
Acetate (MAM) treated animals. 
LH 
Pup 10 Group Sex Cage Pup Group Sex Cage Pup 10 Group Sex Cage 10 
A1 MAM Male 1 814 MAM E17 Male· 26 K98 SHAM E15 Female 47 
C22 MAM Male 1 H62 MAM E17 Male 26 N129 SHAM E15 Female 47 
G52 MAM Male 1 T183 MAM E17 Male 26 U195 SHAM E15 Female 47 
X219 MAM Male 1 0136 MAM E17 Male 26 U194 SHAM E15 Female 47 
C21 MAM Male 4 F50 MAM E17 Fern 28 U197 SHAM E15 Female 48 
L104 MAM Male 4 178 MAME17 Fern 28 K101 SHAM E15 Female 48 
P145 MAM Male 4 Mt21 MAM E17 Fern 28 48 
X222 MAM Male 4 V205 MAM E17 Fern 28 48 
A2 MAM Male 6 816 MAM E17 Fern 29 K100 SHAM E15 Female 49 
C23 MAM Male 6 H70 MAME17 Fern 29 N130 SHAM E15 Female 49 
G54 MAM Male 6 0140 MAME17 Fern 29 49 
P142 MAM Male 6 V206 MAME17 Fern 29 49 
A4 MAM Male 8 815 MAM E17 Fern 31 W213 SHAME17 Male 51 
G53 MAM Male 8 H68 MAME17 Fern 31 J82 SHAM E17 Male 51 
L105 MAM Male 8 M116 MAM E17 Fern 31 51 
X221 MAM Male 8 T188 MAME17 Fern 31 51 
C25 MAM Female 11 F48 MAM E17 Fern 32 J83 SHAME17 Male 52 
L109 MAM Female 11 176 MAME17 Fern 32 R161 SHAM E17 Male 52 
P151 MAM Female 11 M119 MAM E17 Fern 32 52 
031 MAM Female 11 V207 MAM E17 Fern 32 52 
C24 MAM Female 12 K93 SHAM E15 Male 39 J84 SHAME17 Male 53 
029 MAM Female 12 N124 SHAM E15 Male 39 R162 SHAM E17 Male 53 
G60 MAM Female 12 U190 SHAM E15 Male 39 W211 SHAM E17 Male 53 
P149 MAM Female 12 S176 SHAM E15 Male 39 R166 SHAM E17 Male 53 
A6 MAM Female 14 U193 SHAM E15 Male 40 R164 SHAM E17 Male 54 
035 MAM F.emale 14 K92 SHAM E15 Male 40 0152 SHAM E17 Male 54 
L110 MAM Female 14 40 R165 SHAM E17 Male 54 
X225 MAM Female 14 40 W212 SHAM E17 Male 54 
A5 MAM Female 15 K95 SHAM E15 Male 42 J87 SHAM E17 Female 55 
033 MAM Female 15 S170 SHAM E15 Male 42 0157 SHAM E17 Female 55 
G59 MAM Female 15 S174 SHAM E15 Male 42 55 
P150 MAM Female 15 U192 SHAM E15 Male 42 55 
F43 MAM Male 19 K96 SHAM E15 Male 43 J88 SHAM E17 Female 56 
175 MAM Male 19 N125 SHAM E15 Male 43 R167 SHAM E17 Female 56 
0132 MAM Male 19 43 W214 SHAM E17 Female 56 
V202 MAM Male 19 43 0155 SHAM E17 Female 56 
810 MAM Male 22 K97 SHAM E15 Male 44 J86 SHAME17 Female 57 
H63 MAM Male 22 N122 SHAM E15 Male 44 J91 SHAME17 Female 57 
0135 MAM Male 22 44 0159 SHAM E17 Female 57 
T185 MAM Male 22 44 W215 SHAME17 Female 57 
812 MAM Male 24 N126 SHAM E15 Fern 45 J90 SHAM E17 Female 58 
174 MAM Male 24 N127 SHAM E15 Fern 45 0158 SHAME17 Female 58 
T181 MAM Male 24' S179 SHAM E15 Fern 45 58 
V203 MAM Male 24 U199 SHAM E15 Fem 45 58 
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2.2.1d Behavioural Analyses 
2.2.1d(i) Locomotor Activity 
Locomotor activity was measured in complete darkness (LUX value of zero using 
Testo 435 meter) in 16 clear Perspex boxes (40x40x30cm) located on infrared fields. 
Four boxes were placed on each field, which were monitored using overhead 
infrared cameras. The cameras fed into a Quad compressor unit, which in turn fed 
a PC running the image analysis application Ethovision (Noldus). Ethovision digitizes 
the path made by animals at a rate of 25 frames per second and uses this to 
calculate various different parameters. 
At the beginning of a trial, rats were placed in the centre of the arena and the 
behaviour exhibited during a 30 min habituation period was recorded. For the adult 
rats, at the end of this period they were removed, given an injection of vehicle or 
MK-801 (0.1 mgjkg) and returned to the same arena, and behaviour was recorded 
for a further 120 min. The distance travelled in the arena by the animals was 
analyzed in 5-min intervals. 
2.2.1d(ii) Prepulse Inhibition of the Acoustic Startle Response 
Testing was conducted in eight ventilated sound-attenuated startle chambers (San 
Diego Instruments, CAl, controlled by SOl software (SR-LAB, San Diego Instruments, 
CAl. Each chamber contained a clear Plexiglas tube mounted on a platform in a 
ventilated and illuminated chamber. Acoustic pulses and prepulses were delivered 
via a speaker located above the tube. Movement inside the tube was detected by a 
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piezoelectric accelerometer below the frame. The amplitude of the whole body 
startle to an acoustic pulse was defined as the maximum of 100 one-millisecond 
accelerometer readings collected from pulse onset. The volume of the loud 
speakers had been previously measured using a sound level meter (Radioshack) and 
the speakers in all 8 boxes were calibrated to be within 3dB of each other. 
The procedure comprised two sessions: the habituation and the test sessions 
{adapted from (Swerdlow and Geyer 1998), separated by 24 hours. On day one, the 
rats were placed in startle chambers (San Diego Instruments, Inc., San Diego, 
California) and habituated to a background noise level of 67 dB for 15 minutes, 
followed by eight startle trials (40 ms, 120 dB); the intertrial interval (ITI) averaged 
15s (range 10-20s). The total session lasted seventeen minutes. 
For the test session, a five minute acclimation period (white noise 67dB) preceded a 
sequence of six startle trials. Prepulse inhibition of startle (PPI) was quantified using 
background noise (white noise 67dB), 120 dB startle tone {white noise burst, Pulse 
(P)) of 40 milliseconds duration, prepulses (ppP) ranging from 4 to 16 dB above 
background of 40 milliseconds duration, and inter-trial intervals of 10-15 seconds. 
Prepulses preceded 75% of the startle trials with an inter-stimulus interval of 120 
milliseconds. A sequence of six startle tones ended the session. 
Percentage prepulse inhibition was calculated at each of the four prepulse 
intensities using the following formula: 
% PPI = 100 * [(P - ppP) / P] where P = pulse and ppP = prepulse 
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2.2.1e Statistical analysis 
All statistical analysis were calculated using STATISTICA v.7 (Statsoft Inc.) and all 
data are expressed as mean ± standard error of the mean (s.e.m.). In general, data 
were analysed using analysis of variance, followed, when appropriate, by planned 
comparisons (univariate test of significance) with between-subject factors of group 
(MAM; SHAM) vs. treatment (ElS; El7) or sex (M; F). Significant interactions were 
further submitted to analyses of simple effects and, if appropriate, to planned 
comparisons. In all cases, P<O.OS indicated significance. 
2.2.1e(i) Litter Size and Brain and Body Weight 
As body weights between albino (Sprague Dawley, Wistar) and Lister Hooded rats 
differ considerably at the same age, brain and body weights were analysed 
separately for each strain using two-way analyses of variance with between subject 
factors of group (MAM; SHAM), treatment (ElS; E17) and sex (M; F). Litter size was 
analysed using two-way analyses of variance with between subject factors of strain 
(SO; LH) so they could be directly compared. 
2.2.1e(ii) Locomotor Activity 
A general linear model approach was used for all multivariate ANOVAs calculated 
for Ethovision parameters. 
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Spontaneous locomotor activity in juvenile animals - Data were submitted to a two-
way between-subjects analysis of variance with factors of sex (M; F) and MAM 
treatment (E1S; E17). This analysis was conducted for each strain separately. 
MK-801-induced changes in locomotor activity - Separate analyses were conducted 
on the 'Habituation' phase and 'Run' phases of the experiment. Data generated 
during the habituation phase was submitted to two-way between-subjects analysis 
of variance for each strain. Data generated for each strain during the run phase was 
submitted to a three-way ANOVA with factors of sex (M; F), treatment (MAM E1S; 
SHAM E1S; MAM E17; SHAM E17) and drug (MK801; vehicle). Planned comparisons 
were conducted by comparing equivalent MAM and SHAM treated groups. 
2.2.1e(iii) Prepulse Inhibition 
Prepulse Inhibition (dB) and maximal startle amplitude (arbitrary units) were 
compared across SHAM and MAM-exposed rats using three-way mixed-repeated 
measures ANOVA. The factors were treatment (MAM-E1S; MAM-E17; SHAM), sex 
(M; F) and prepulse intensity (+4, +8, +12, +16 dB over baseline) in juvenile and 
adult rats independently. These analyses were repeated for both LH and CD-SO rats 
separately. Startle amplitude was calculated as the average of the six pulse (P) 
trials. Significant main effects were followed with planned comparisons against 
control; significant interactions were followed by analysis of simple effects and, if 
significant, planned comparisons against control. 
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2.3 Results 
2.2.1 Experiment 1: Strain Comparison in 
Methylazoxymethanol Acetate (MAM) treated animals 
2.3.1a Body Weights, litter size. 
Analysis showed no significant difference in the body weight gain (repeated 
measures_ between MAM and SHAM treated rats in the male or female Charles 
Derived Sprague Dawley and Lister Hooded rats (F(3,53) = 0.012, p>O.5) (F(3,52) = 
0.268, p>0.5) (F(3,53) = 0.046, p>O.5) (F(3,52) = 1.422, p>O.l) respectively. There 
was also no effect of strain (F(1,40) = 1.688, p>O.l) or group (F(3,40) = 0.980, p>O.l) 
on litter size (MAM E15, 11.44 ± 0.55, MAM E17, 12.18 ± 0.64, SHAM E15, 12.38 ± 
0.63, SHAM E17, 13.00 ± 0.76). 
2.3.1b Brain Weights 
2.3.1b(i) Juvenile Brain Weights 
There was a significant effect of MAM administration on brain weight in both Lister 
Hooded and Charles Derived Sprague Dawley rats (Figure 1). The analyses revealed 
that treatment with MAM on either E15 or E17 significantly decreased brain 
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weights in both male and female Lister Hooded rats (F(3,40) = 17.80, p<O.OOOl). 
There was an overall effect of sex (F(1,40) = 18.26, p<O.OOl) with brains from 
female rats weighing less than those from males. However these factors did not 
interact (F(3,40)<0.1). Planned comparisons showed that both El5 and E17 MAM 
LH rats had significantly decreased brain weights compared to their SHAM 
equivalents and E15 MAM treated rats had significantly smaller brains compared 
with El7 MAM treated rats. In Charles Derived SO rats, there was an effect of sex 
(F(l,39) = 19.17, p<O.OOOl) in that female brains weighed less, and of treatment 
(F(3,39) = 82.33, p<O.OOOl) where MAM treated brains weighed less but there was 
no interaction between MAM treatment and sex (F(3,39) = 0.18, p>O.s). Planned 
comparisons showed that E15 MAM CD-SO rats had significantly decreased brain 
weights compared to their SHAM equivalents (male, p<O.OOl, female, p<O.OOl). 
Male rats exposed to MAM on E17 did not differ from their SHAM counterparts. As 
body weight was not altered by treatment, brain weights were not expressed in 
relation to total body weight. 
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Figure 1: Brain weights in 
(a) juvenile and (b) adult 
Lister Hooded and (c) 
juvenile and (d) adult 
Charles Derived Sprague 
Dawley rats treated with 
MAM on E15 or E17 
Effect of MAM treatment on 
days El5 or El7 in (a) 
juvenile (MAM n = 8; SHAM 
n = 4) and (b) adult Lister 
Hooded rats (MAM n = 8; 
SHAM n = 8) or (c) juvenile 
(MAM n = 8; SHAM n = 4) 
and (d) adult Charles River 
derived Sprague Dawley SO 
rats (MAM n = 8; SHAM n = 
8) on brain weights (g). Data 
are presented as mean ± 
standard error of the mean. 
Significant differences are 
indicated on the Figure as 
follows:* P<O.05; ** P<O.Ol; 
*** P<O.OOl. 
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2.3.1b(i) Adult Brain Weights 
For the Lister Hooded rats, there was an effect of sex (F(1,48) = 11.804, p<O.Ol) and 
treatment group (F(3,48) = 2.96, p<O.05) (Figure 1B) but no interaction between the 
two (F(3,48) = 1.765, p>O.l). Planned comparisons showed that only female E15 
MAM LH rats had significantly decreased brain weights compared to their SHAM 
equivalents (Figure 1B). In Charles Derived SO rats, there was an effect of sex . 
(F(1,48) = 23.89, p<O.OOOl) and treatment group (F(3,48) = 61.47, p<O.OOOl) (Figure 
10) but no interaction between the two (F(3,48) = 0.37, p>0.5). Planned 
comparisons showed that E15 MAM CD-SD rats had significantly decreased brain 
weights compared to their SHAM equivalents (Fig 10) but only male rats exposed to 
MAM on E17 differed from their SHAM counterparts with no difference being seen 
in the E17 females. As body weight was not altered by treatment, brain weights 
were not expressed in relation to total body weight. 
2.3.1b(iii) Neuropathology 
The macroscopic photographs taken of the dorsal surface of the rat brains indicated 
that the E15 MAM produced large changes in brain structure in both male and 
female juvenile (Figure 2A) and particularly in adult CD Sprague Dawley rats (2B). In 
contrast, E17 MAM produced much smaller changes in juvenile (Figure 2B) and 
adult Lister Hooded rats (Figure 3B). 
Initial studies on SHAM and MAM treated male CD Sprague Dawley E17 rats 
indicated that there was a decrease in mPFC area and thickness, a reduced area at 
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the level of the dorsal hippocampus and a large increase in the size of the lateral 
ventricles. This was followed up with a larger study using a second cohort of 
animals.. There was an effect of treatment group on the mPFC (F(l,14) = 6.008, 
p<0.05) (Figure 3a), the dorsal and ventral hippocampi, (F(l,14) = 21.170, p<O.OOl) 
and (F(l,14) = 11.452, p<O.Ol), respectively, (Figure 3b,c) and a significant increase 
in the area of the lateral ventricles (F(l,14) = 19.16648, p<O.OOl) (Figure 3d). Some 
of the images at the level of the Prefrontal cortex, dorsal hippocampus and lateral 
ventricles are illustrated in Figure 3E. 
Juvenile E15 Lister Hooded Rat Brains Juvenile E17 Lister Hooded Rat Brains 
MALE FEMALE MALE FEMALE 
Figure 2: Representative photographs of juvenile Lister Hooded and Charles 
Derived Sprague Dawley rat brains. 
Effect of MAM treatment on days E15 (2A) or E17 (2B) in juvenile Lister Hooded rats 
or juvenile Charles River derived Sprague Dawley rats. There is clear overall 
shrinkage of the brains after E15 MAM and this is most pronounced in E15 Charles 
Derived SD rats. There are also some changes in brain structural after E17 MAM, 
but this is much less severe that was observed with E15 MAM. 
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Figure 3. Structural analysis of quantification of the size of various anatomical 
brain structures in SHAM and E17 MAM treated Charles Derived Sprague Dawley 
rats. 
The area of A. prefrontal cortex, B. dorsal hippocampus, C. ventral hippocampus 
and D. lateral ventricles and E. Representative cresyl violet stained coronal sections 
in SHAM and E17 MAM Charles Derived Sprague Dawley rats . Data are expressed as 
mm2 from the left and right hemispheres of the rat brain and the mean of both 
hemispheres is also shown. There were clear decreases in the size of the area of 
the prefronta l cortex, dorsa l and vent ral hippocampus and a large increase in the 
area of the lat eral ventricles. Dat a are presented as mea n ± standard erro r of the 
mean . Significant differences are indicated on the Figure as follows:* P<O.05; ** 
P<O.Ol; *** P<O.OOl. 
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2.3.1c Locomotor Activity (LMA) 
2.3.1c(i) Juvenile LMA 
In the juvenile CD Sprague Dawley rats there was no effect of sex (F(l,39) = 2.8156, 
p>O.l), but there was an effect of treatment group (F(l,39) = 4.0389, p<0.05) and 
an interaction between the two (F(3,39) = 4.1608, p<0.05). Further planned 
comparisons showed that the MAM E15 treated male rats showed significant 
hyperactivity in a novel arena throughout the 30 minute habituation period but 
there was no effect in the E17 treated male rats (Figure 4B). In the female rat, the 
E15 SHAM rats seemed to be more hyperactive than the other groups at the first 
time point only (Figure 4B). There was no MAM-induced change in spontaneous 
exploratory locomotion in the juvenile Lister Hooded group (F(3,40) = 1.234, p>O.l) 
(Figure 4A) but there was an effect of sex (F(1,40) = 9.195, p<O.Ol). There was also 
no interaction between sex and treatment group (F(3,40) = 0.362, p>0.5). 
2.3.1c(ii) MK-801 Adult LMA 
There was an effect of treatment group and sex on LMA during the habituation 
phase in LH rats (F(3,94) = 6.156, p<O.OOl) and (F(l,94) = 18.060, p<O.OOOl) 
respectively. As expected, MK-801 produced a marked hyperactivity in the two 
hours after administration such that post-injection of MK-801 caused an effect of 
treatment group, sex and drug (F(3,93) = 7.1817, p<O.OOl), (F(l,93) = 76.7405, 
p<O.OOOl) and (F(l,93) = 82.8638, p<O.OOOl) respectively on the total LMA over 2 h. 
Further comparisons showed there was no significant difference between male LH 
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E15 MAM and SHAM or LH E17-MAM or E17-SHAM rats treated with MK-801 
(Figure 5A). There were however significant differences between E15 and El7 LH 
female MAM rats treated with MK-801 compared to their equivalent SHAMS 
(Figure 5B). Treatment with MK-801 increased hyperactivity in male MAM El7 
treated rats and female rats treated with MAM on both E15 and E17 (treatment 
group F{3,96) = 3.094, p<0.05), (sex F{l,96) = 33.595, p<O.OOOl) and (drug group 
F{l,96) = 66.507, p<O.OOOl). Further comparisons showed significant differences 
between E15 and El7 CO female MAM rats treated with MK-801 compared to the 
equivalent SHAMS (Figure 50). 
There was an effect of treatment group and sex during the habituation phase in SO 
rats in that the females and MAM El5 treated rats were more hyperactive (F{3,96) 
= 25.643, p<O.OOOl) and (F{l,96) = 7.417, p<O.Ol) respectively and there was no 
effect of drug group (F{l,96) = 0.880, p>O.l) (Figure 5). 
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Figure 4: Locomotor activity in juvenile Lister Hooded and Charles Derived 
Sprague Dawley rats treated with MAM on E15 or E17 
Effect of MAM treatment on days E15 or E17 in (a) juvenile male and female Lister 
Hooded rats or (b) juvenile male and female Charles River derived Sprague Dawley 
rats on locomotor activity. Data are presented as mean ± standard error of the 
mean of total distance travelled (em) (n = 8 for all MAM groups and n = 4 for all 
SHAM groups). Symbols as follows: male MAM E15 treated rats (e); male SHAM 
E15 treated rats (0); male MAM E17 treated rats (_); male SHAM E17 treated rats 
(0); female MAM E15 treated rats (e); female SHAM E15 treated rats (0); female 
MAM E17 treated rats (_); female SHAM E17 treated rats (0). Significant pair-wise 
comparisons between SHAM and MAM E15 groups are indicated on the Figure as 
follows:* P<O.05; ** P<O.Ol; *** P<O.OOl. 
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Figure 5: Locomotor activity in adult Lister Hooded and Charles Derived Sprague Dawley rats treated with MAM on E15 or E17 
Effect of MAM treatment on days E15 or E17 in (a) adult male, (b) adult female Lister Hooded rats, (c) adult male and (d) adult female Charles 
River derived Sprague Dawley rats on locomotor activity. Data are presented as mean ± standard error of the mean of total distance travelled 
(em) (n = 8 for all MAM groups and n = 6 for all SHAM groups). Symbols as follows: male MAM rats treated with MK801 (e); male SHAM rats 
treated with MK801 (0); male MAM rats with vehicle (_); male SHAM rats with vehicle (0); female MAM rats with MK801 (e); female SHAM 
rats with MK801 (0); female MAM rats with vehicle (_); female SHAM rats with vehicle (0) . Significant pair-wise comparisons between are 
indicated on the figure as follows: MK-80l treated SHAM vs. MK-80l treated MAM * P<O.05; ** P<O.Ol; *** P<O.OOl. 
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2.3.1d Prepulse Inhibition 
2.3.1d(i) Juvenile PPI 
As group sizes for the SHAM group in this study were limited (n = 4 for the SHAM 
groups; n = 8 for the MAM group for both LH and COSO rats), statistics were 
performed to determine if the data from SHAM E15 and SHAM E17 could be. 
collapsed into a single SHAM group for comparison purposes. There was no effect 
of group in the Lister hooded (F(1,48) = 1.893, p>O.l) or the Charles Derived 
Sprague Dawley rats (F(1,48) = 1.092, p>O.l), therefore the SHAM groups were 
combined to give an n = 8. 
There was no effect of treatment with MAM (F(2,206) = 1.5577, p>O.l) or sex 
(F(l,206) = 0.0263, p>O.5) in the LH group. There was also no effect of treatment 
group or sex on prepulse inhibition in juvenile COSO rats (F(2,210) = 0.417, p>0.5) 
and (F(l,210) = 2.178, p>O.l), respectively (Figure 6B). 
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Figure 6: Prepulse inhibition in juvenile (a) Lister Hooded and (b) Charles Derived Sprague Dawley rats treated with MAM on E15 or E17 
Effect of MAM treatment on days El5 or E17 in juvenile (a) Lister Hooded rats or (b) Charles River derived Sprague Dawley rats on percentage 
pre-pulse inhibition. Also presented are the startle amplitudes for each treatment (arbitrary units). Data are presented as mean ± standard 
error of the mean (n = 8 for all MAM groups and n = 4 for all SHAM groups). 
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Figure 7: Prepulse inhibition in adult (a) Lister Hooded and (b) Charles Derived Sprague Dawley rats treated with MAM on E15 or El7 
Effect of MAM treatment on days E15 or E17 in adult (a) Lister Hooded rats or (b) Charles River derived Sprague Dawley rats on percentage 
pre-pulse inhibition. Also presented are the startle amplitudes for each treatment (arbitrary units). Data are presented as mean ± standard 
error of the mean (n = 16 for all MAM groups; n = 12 for all SHAM groups). Significant differences as follows:* P<O.05; ** P<O.Ol; *** P<O.OOl. 
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2.3.4d(ii) Adult PPI 
Statistics were also performed on the adult SHAM E15 and E17 groups to see if they 
could be combined to provide one SHAM group as some of the boxes crashed 
midway through a session. There was an effect of strain (F(l,374) = 26.075, 
p<O.OOOl) but no effect of treatment group or sex, (F(l,374) = 0.047, p>0.5) and 
(F(l,374) = 1.311, p>O.l) respectively therefore the groups were combined for all . 
further statistical analyses with all data shown in Figure 7B. 
There was an effect of sex on prepulse inhibition in adult LH rats (F(1,424) = 7.540, 
p<O.Ol), respectively, but no effect of treatment group (F(2,424) = 1.776, p>O.l). 
However there was a significant interaction between sex and treatment group 
(F(2,424) = 5.941, p<O.Ol). Further planned comparisons showed that this 
significant effect was only in the male E15 rats at prepulse 1 (figure 7A). For the CD 
Sprague Dawley rats, there was an effect of sex (F(l,360) = 8.159, p<O.Ol) but no 
effect of treatment group (F(2,360) = 2.259, p>O.106). Again, there was an 
interaction between treatment group and sex (F(2,360) = 11.522, p<O.OOOl). 
Planned comparisons showed that this effect was due to the male CD Sprague 
Dawley rats (figure 7B). 
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2.4 Discussion 
The present data show that maternal treatment with methylazoxymethanol acetate 
(MAM) leads to behavioural, neuroanatomical and pharmacological alterations in 
the resultant offspring of Charles Derived Sprague Dawley rats. These changes 
include decreased brain weights, decreased size of the hippocampus, PPI deficits 
and hypersensitivity to MK-801 measured by changes in locomotor activity; changes 
that have translational relevance to some of the core symptoms of schizophrenia 
(Moore et al., 2006). Furthermore, the absence of these deficits before puberty in 
the same rats indicates that this model may also replicate the post-adolescent 
onset of psychosis (Wood., 2008).There was no effect of MAM treatment on litter 
size and all groups gained body weight at the same rate, suggesting that there were 
no adverse effects of the toxin on gestation or maternal suckling and care. MAM 
treatment produced a reduction in brain weight in all juvenile Lister Hooded brains, 
but surprisingly this difference disappeared in the adult males. There was also a 
reduction in brain weight in MAM El5 and E17 Charles Derived rats very similar to 
those previously reported in Sprague Dawley (Gourevitch et al., 2004) and Fischer 
344 rats (Moore et al., 2006). The structural changes in the brain (reduced size of 
the prefrontal cortex and dorsal hippocampus and increased ventricular size) are 
also consistent with the changes reported in the literature in CD-SO (Gourevitch et 
al., 2004; Le Pen et al., 2006) and Fischer 344 rats (Moore et al., 2006). 
Generally, there was a smaller effect of MAM treatment on the behavioural 
measurements taken in Lister Hooded than in CD-SO rats. MAM had no effect on 
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locomotor activity in pre-pubertal or adult male LH rats. However, CD-SD MAM 
treated rats were hypersensitive to MK-801 at adulthood. Hyperlocomotor activity 
is a plausible correlate of the psychomotor agitation seen in schizophrenia. It is 
therefore proposed that the hyperlocomotion observed in E17 MAM rats may 
reflect positive symptoms in schizophrenic patients, in particular, since it has a post-
pubertal onset and is exacerbated by NMDA receptor antagonists (Goff and Coyle., 
2001). Le Pen et al., (2006) also showed that locomotor activity after MK-801 
administration was significantly higher in MAM compared to sham-treated rats in 
adulthood but not before puberty. Another study found that MAM rats are more 
responsive to D-amphetamine (Flagstad et al., 2004). Schizophrenic patients are 
hypersensitive to D-amphetamine both behaviourally and in terms of subcortical 
DA release (Breier et al., 1997; Angrist et al., 1980). It is also thought that 
psychological stress may exacerbate psychotic symptoms (Norman and Malia., 
1993) and it has also been reported that MAM treated rats are hypersensitive to 
mild stress (Le Pen et al., 2006). 
Abnormalities of sensory-motor gating as measured by pre-pulse inhibition of the 
acoustic startle response are one of the most robust endophenotypic markers in 
schizophrenia (Braff et al., 2001). The current data (figure 7B) demonstrate that 
male Charles Derived E17 MAM rats exhibit a significant deficit in PPI at different 
prepulse intensities, consistent with previous findings (Le Pen et al., 2006) as well as 
with other neurodevelopmental models of schizophrenia such as prenatal immune 
challenge, post-weaning social isolation and neonatal lesions of the ventral 
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hippocampus (Borrell et al., 2002; Van Den et al., 2003). This study suggests that 
the changes seen in E17 MAM treated rats are strain-specific since they do not 
occur in male LH rats under identical experimental conditions.: small differences in 
brain weight were found in juvenile LH compared to those seen in E15 MAM-
treated C ~ - S O O rats and only the female LH rats showed a statistically significant 
decrease in brain weight in adulthood. Strain differences in rats have been seen in 
many different assays. For example, in the Isolation Rearing model of 
schizophrenia, Weiss et aI., (2000) showed that LH isolates had significantly higher 
levels of locomotor activity compared to C ~ - S O O isolates. Both C ~ - S O O and LH rats 
showed isolation-induced PPI deficits but this was maintained on repeated testing 
only in the C ~ - S O O isolates. C ~ - S O O rats were also more sensitive to low doses of 
apomorphine than LH rats. 
The differential effects of MAM in the two strains used in this study may be due to 
a number of factors. Whilst it is possible that the pace and/or pattern of 
neurodevelopmental processes may differ between the two strains, it seems more 
likely that the differences are pharmacokinetic in nature. MAM is metabolised to a 
reactive species that passes through the placenta and methylates purine bases on 
RNA and DNA (Cannon-Spoor and Freed., 1984; Spatz and Laqueur., 1968). It may 
be that MAM is less susceptible to metabolism in LH rats or that the drug and/or its 
metabolites are less easily absorbed or less able to cross the placenta. Surprisingly, 
the LH rats also seemed to display a 'recovery' as the brain weight deficit seen in 
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juvenile MAM treated LH rats was lost in adulthood, possibly reflecting enhanced 
neurogenesis during adolescence. 
Female LH and Co-so rats were more sensitive to the locomotor stimulating effects 
of MK-801 in comparison to males whereas no deficits were seen in PPI in females. 
Gender differences in schizophrenia have been reported in the literature ever since 
Kraepelin first described dementia praecox as predominantly a disorder of young 
men. Subsequently, it has been one of the most consistent findings in the 
epidemiology of the disorder. Female schizophrenia patients seem to have a 3-4-
year delay of symptom onset and first hospitalization compared with males, and a 
second peak at the onset of menopause (Hafner et al., 1993). 
The acute effects of MAM are dose-related as well as being time-limited, lasting 
approximately 24h with maximal effects occurring 12h after dosing and only 
neurons actively dividing during this exposure time are thought to be damaged by 
the treatment. This is particularly advantageous as the observed abnormalities can 
be relatively precisely correlated with the different stages of neurodevelopment. 
We have shown that treatment on E1S results in deficits that are different to those 
seen on E17. In particular, the reduction in brain weight in both juvenile and adult 
MAM treated co-so rats is much greater after treatment at E1S than at E17. It has' 
also been shown that administration of MAM at E1S severely impairs spatial 
memory as well as causing a significant reduction in brain weight including a 
decreased thickness in all cortices and large heterotopias in the hippocampus 
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(Gourevitch et al., 2004) and a severe reduction in entorhinal cortex, prefrontal 
cortex and striatum volumes (Jongen-Relo et al., 2004). Other groups examining the 
behaviour of E15 MAM treated animals have shown impairments of place-
navigation in a swim maze (Mohammed at al 1986) and a marked impairment in 
rule learning as well as in reversal learning and passive avoidance tasks (Moore et 
al., 2006). However, the consensus is that administration of MAM between El2 
and 15 has no validity as a behavioural model for schizophrenia since this leads to 
marked microencephaly and gross motor impairments, including ataxia and a 
blunted startle reflex (Jongen-Relo et al., 2004; Moore et al., 2006). Also, despite 
these morphological and behavioural abnormalities, deficits in prepulse inhibition 
were only apparent in El7 treated animals, indicating that the timing of MAM 
administration is very important to outcome. 
Timing of injection on E17 could also be important as alluded to by a study by Spatz 
and Laqueur (1968). They found that one feature of the microencephaly induced by 
MAM was its uniformity among littermates. They also stated that the differences in 
the degree of microencephaly between litters were most likely due to the variation 
in timing of injection. These differences in microencephaly could also result in 
differences in behaviour between litters whereas the uniformity among littermates 
could result in litter effects. 
In conclusion, the observations from this study and those of other groups indicate 
that a disturbance in neurodevelopment induced by MAM administration on El7 
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leads to several behavioural and neuroanatomical changes similar to the core 
pathophysiological changes characteristic of schizophrenia (Featherstone et 01./ 
2007; Styner et 01./ 2005). However, our work makes it clear that care must be 
exercised in the selection of rat strain and gender to be used since male LH rats are 
essentially resistant to MAM E17 treatment. Further work described in the next 
chapters will concentrate on the cognitive consequences of MAM El7 treatment. 
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Chapter 3: Spatial Reversal 
Learning 
3.1 Introduction 
Cognitive inflexibility, described as the inability to spontaneously withhold or 
modify a behaviour in response to changing situational demands, is associated with 
various psychiatric disorders, most notably schizophrenia, depression, and 
obsessive-compulsive disorder (Boulougaris., 2008). It is a core component of 
schizophrenia and in patients it is the single best predictor of long-term outcome of 
the disease (Holthausen et 01., 2006). It is also of particular interest in that unlike 
many other cognitive deficits in schizophrenia, reversal learning - which is used as 
an indicator of cognitive (in)flexibility - impairments appear to be unrelated to a 
general impairment in intelligence and are statistically related to clinical ratings of 
negative symptoms, including disorganisation and thought disorder (Leeson et 01., 
2009). The clarification of the underlying mechanisms of cognitive flexibility could 
therefore be of major importance for the understanding of its etiology and 
treatment. 
Reversal learning defines a fairly broad set of tasks of discrimination learning, 
where at some point during learning, reinforcement contingencies are swapped 
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one or more times between choice options. A great benefit of reversal learning 
paradigms is the operational similarity of such tasks between species, including 
humans. It has been used as a measure of behavioural flexibility in humans (Rogers 
et al., 2000; McKirdy et al., 2009, Leeson et al., 2009), nonhuman primates (Owen 
et al., 1991, Dias et al., 1996a,b; Clarke et al., 2005, 2008), and rats (Birrell and 
Brown, 2000; Idris et al., 2005; Boulougouris et al., 2007). Rodent tasks of reversal 
learning usually comprise two distinct components, an initial phase that requires 
memory of a previously learned reward contingency, followed by a reversal phase, 
in which the reward contingency is then reversed and the previously correct 
contingency is now incorrect and vice versa. Animals are required to inhibit a 
previously rewarded strategy and acquire the new strategy. Thus, effective 
performance requires animals to demonstrate flexibility, attention and motivation 
to suppress a previously learned response and implement a new response (Jones et 
al., 1991). Reversal learning ability can also be assessed using other tasks such as 
the reversal stages within the attentional set-shifting paradigm (Birrell and Brown, 
2000). 
Impairments in behavioural flexibility observed in schizophrenia have been 
attributed to perturbation in frontal lobe functioning. Post-mortem and functional 
imaging studies of schizophrenic brains have revealed gray matter abnormalities in 
the prefrontal cortex (PFC), which likely contribute to the impairments seen in 
executive function tasks such as Wisconsin Card Sorting Test (WCST) and Trail 
Making Test (TMT) (Bonilha et al., 2008; Rusch et al., 2007). Lesion studies in 
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rodents and monkeys, electrophysiological studies in rats and mice and studies of 
brain-damaged patients as we" as neuroimaging in healthy volunteers have shown 
that reversal learning is well-known to engage a specific neural circuitry including 
the orbitofrontal cortex, amygdala and striatum (Clarke et al., 2008; Dias et al., 
1996; Chudasama and Robbins., 2003; McAlonan and Brown., 2003). However, 
recent findings from both human and animal studies indicate that complex forms of 
behavioural flexibility mediated by the frontal lobes are also dependent on a 
number of subcortical systems that interact with the PFC. These include midline 
thalamic nuclei, dorsal and ventral regions of the striatum, and the 
mesocorticolimbic dopamine (DA) system. It is of note that abnormalities in each of 
these systems have also been proposed to contribute to the pathophysiology of 
schizophrenia (Andreasen et al., 1990; Shenton et al., 2001; Danos et al., 2003; 
Bonilha et al., 2008). 
Converging evidence from a number of studies has specifically implicated the 
orbitofrontal cortex (OFC) for successful reversal learning ability in rodents. It has 
been shown that lesions of the orbital prefrontal cortex (OPFC) impair the reversal 
learning ability within the attentional set-shifting task (McAlonan and Brown., 2003) 
as we" as visual discrimination tasks (Chudasama and Robbins., 2003; Boulougouris 
et al., 2007). These results are concurrent with those of Bohn and co-workers, 
showing that lesions of the OFC impair reversal learning in an operant lever 
pressing-based task (Bohn et al., 2003) while other studies using an olfactory-
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guided go/no-go discrimination task, show that rats with OFC lesions are impaired 
during the second, but not the first, reversal stage (Ferry et al., 2000). 
In contrast to the OFC, investigating the involvement of the rat medial prefrontal 
cortex (mPFC) has produced somewhat ambivalent effects on simple reversal 
learning. Despite earlier studies having found that lesions in the mPFC produce 
reversal deficits (Kolb et al., 1974, Nonneman et al., 1974), more recent studies 
have reported both reversal deficits (Bussey et al., 1996; Ferry et al., 2000; Li and 
Shao., 1998) as well as unimpaired reversal (Birrell and Brown 2000, Boulougaris et 
al., 2007; Floresco et al., 2008). The mPFC of rats, however, consists of several sub-
areas that are different from each other in both cytoarchitecture and neural 
connectivity, suggesting a functional dissociation among the mPFC sub-areas. Li and 
Shao (1998) have shown no difference in acquisition between control and mPFC 
lesioned rats. However, lesions of either the pre-limibic or the infralimbic mPFC 
produced a marked deficit in the reversal task. This behavioural deficit was not 
found in rats with lesions of the anterior cingulate. The results indicate that the 
mPFC of rats is not essential for discrimination learning, but that each of the two 
. ventral sub-areas of the mPFC, pre-limbic and infra-limbic, play a critical role in 
reversal learning. 
Variants of reversal learning may also engage other brain regions; spatial reversal is 
often associated with the hippocampus, and probabilistic reversal engages the 
ventrolateral PFC (Cools et al., 2002), as does serial reversal learning (Rygula et al., 
83 
Chapter 3: Spatial Reversal Learning 
2010). It has been suggested that spatial reversal learning may be more sensitive to 
hippocampal dysfunction than spatial acquisition (O'Keefe and Nadel., 1978; 
Whishaw and Jarrard., 1996). This is supported by studies that have investigated 
the effects of the N-methyl-O-aspartate (NMOA) receptor antagonist O-(-)-amino-S-
phosphonopentanoic acid (APS) on variants of the hidden-platform water maze 
task. Although infusion of AP5 blocked the induction of hippocampal LTP and 
impaired acquisition of the spatial reference memory water maze task in naive 
animals (Bannerman et al., 1995), there was no drug effect on spatial learning if the 
animals had received spatial water maze training in a separate and distinct testing 
room, prior to testing with the drug (Bannerman et al., 1995). Schizophrenic 
patients with a hippocampal lesion have been shown to commit significantly more 
perseverative errors when performing on the WCST, than subjects with frontal lobe 
damage (Corcoran and Upton., 1993), confirming that intact hippocampal function 
is required for reversal learning. In addition, lesion of the hippocampus in rats 
produces a significant impairment in working memory tasks (Jackson et al., 1998; 
Sziklas and Petrides., 2002). Therefore, the inability of sub-chronic PCP treated 
animals to perform adequately in a reversal task (Jentsch and Taylor., 2001; Idris et 
al., 2005), may be representative of hippocampal as well as frontal cortical 
dysfunction. 
In terms of animal models that may bear relevance to schizophrenia, Kellendonk et 
al., (2006) have shown that reversal learning was impaired by over-expression of 
the 02 receptor in mouse striatum. The test is also sensitive to other standard 
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models of schizophrenia including PCP administration (Gastambide et 01./ 2012) and 
social isolation reared rats (Jones et 01./ 1991). Reversal deficits have also been 
shown in the MAM-E17 rats by way of the Morris-water maze (Flagsted et 01./2005) 
and the IDEO set shifting task (Gastambide et 01./ 2012). 
Reversal learning can be conducted reliably and fairly quickly in mice, rats and non-
human primates, although typical paradigms are only applied once per animal 
(unless specifically interested in serial reversal effects). As such, reversal learning 
tests may be useful both in the validation of animal models of cognitive impairment 
in schizophrenia, and in the subsequent testing of candidate compounds in these 
models. A recent thrust of drug discovery research has focused on developing novel 
pro-cognitive compounds to treat the cognitive deficits in schizophrenia, and 
preclinical animal models are an essential first step in this process. Given that 
impairments in behavioural flexibility seem to be a core deficit in this disorder, 
modelling these impairments would be extremely beneficial in testing the potential 
efficacy of novel cognitive enhancers. Some work has began to address this topic 
recently (Elsworth et 01./ 2012; McLean et 01./ 2009, Gastambide et 01./ 2013), 
although more evidence of effects of a broader range of pharmacologies in 
different animal models would aid convergent validity. With this is mind, the aim of 
the present study was to investigate a rodent reversal-learning procedure that 
might be used to evaluate novel antipsychotic drugs. The procedure used was an 
adapted version of a serial reversal learning procedure used by Boulougaris et 01./ 
(2007) and the novel antipsychotic was a metabotropic glutamate 5 (mGlu5) 
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receptor positive allosteric modulator, LSN2463359, developed by Eli Lilly. As 
discussed in Chapter 1, the functional interaction of mGlu5 receptors with N-
methyl-D-aspartate {NMDA} receptors has prompted speculation that their 
activation may offer a potential treatment for aspects of schizophrenia. 
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3.2 Methods 
3.2.1 Experiment 1: Effect of Methylazoxymethanol 
Acetate (MAM) treatment on Reversal Learning 
Performance 
3.2.1a Subjects 
Animals were prepared as previously described in Chapter 2. 
30 Male (15 MAM, 15 SHAM), Sprague Dawley (Crl:CD(SD) (SD), Charles River, Kent) 
aged 12 weeks at the start of the experiment were used. All pup information is 
detailed in table 1. Rats were housed in groups of 3 or 4 and had ad libitum access 
to water but were food restricted to 85% of their free feeding weight from 8 weeks 
of age. Food restriction was maintained for the entire duration of the experiment. 
The rats had environmental enrichment (Jolly BalisTM, (Ullico) plastic tubes and 
wooden blocks). The animals were maintained on a 12-hour light dark cycle with 
lights on at 7.00. The experiments were conducted during the same part of the light 
phase each day and a timeline of studies is shown in figure 1. All experiments were 
carried out in accordance with the UK Animals (Scientific Procedures) Act 1986, 
under Home Office project licence 70/6560 and personal licence 71/17650 (N. N. 
Malik). 
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Table 1: Detail of pup treatment groups and lever assignment for Experiment 1: 
Effect of Methylazoxymethanol Acetate (MAM) treatment on Reversal Learning 
Performance. 
Number PUD Tao Group Caoe Lever Assionment 
1 AA156 2408970 Rioht 
2 022 2399156 SHAM E17 3 Left 3 11196 2401669 Left 
4 A4 2400337 Left 
5 Y146 2450846 Rioht 
6 A1 2408525 SHAM E17 6 Rioht 7 AA153 2449934 Riaht 
8 162 2409918 Rioht 
9 KK209 2407523 Left 
10 S119 2403611 MAM E17 17 Rioht 11 N90 2449379 Left 
12 Q104 2403405 Rioht 
13 M83 2450502 Left 
14 GG191 2409229 SHAM E17 21 Rioht 15 U126 2408868 Left 
16 Riaht 
17 H54 2400818 Riaht 
18 88158 2454027 MAME17 26 Left 19 00173 2403289 Left 
20 KK208 2408915 Left 
21 C20 2408695 Left 
22 N92 2458906 MAME17 32 Riaht 23 H53 2403325 Rioht 
24 Riaht 
25 Z147 2449066 Left 
26 C19 2408443 MAM E17 36 Riaht 27 CC162 2447768 Left 
28 F42 2409199 Left 
29 N91 2398865 Left 
30 E34 2403028 MAM E17 41 Left 31 F38 2401938 Left 
32 CC163 2447816 Left 
Day 1 21 34 83 
Birth Weaning Juvenile Adult 
I I 
Juvenile Reversal 
brain Learning 
Figure 1: Timeline of events and studies performed for Experiment 1: Effect of 
Methylazoxymethanol Acetate (MAM) treatment on Reversal Learning 
Performance. 
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3.2.1b Reversal Learning 
3.2.2b(i) Apparatus 
All rats were tested in one of eight operant chambers. Each chamber (30.5x24x21 
cm; Med Associates, Vermont, USA) consisted of Plexiglas walls and ceiling, and a 
metal grid floor over sawdust. A hinged Plexiglas panel (6x6 cm) provided access to 
a food hopper containing food pellets (45 mg Noyes pellets, Sandown Scientific; 
UK). Two retractable levers (4x2 cm) were positioned on either side of the food 
hopper. A light emitting diode (LED) was positioned centrally above each lever and 
a house light was located in the ceiling of each chamber. The chambers were placed 
individually within ventilated sound-attenuating hardboard boxes. A small fan was 
built into each chamber to provide ventilation and mask external noise. Each animal 
was tested in the same operant chamber throughout the study. All boxes were 
controlled by Med-PC software and programmes were written using Medstate 
notation. 
3.2.1b(ii) Reversal Learning Procedure 
Training always started on a Thursday to allow the test phases of the procedure to 
occur in the same week as shown by figure 2. Rats were habituation to the operant 
chambers during magazine training where they learnt to associate the magazine 
with receiving a food pellet. Following this, rats were trained to respond for food on 
a fixed ratio 1 (FR1) schedule of reinforcement with both levers active for 2 days 
after which they moved onto a fixed ratio 3 (FR3) schedule, again for 2 days. The 
session began, in both cases, with the house light being illuminated and 
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presentation of both levers. A single lever press in the case of the FRl program, and 
three lever presses for the FR3 program on either lever, resulted in a food pellet 
being delivered. The session lasted 30 min and the levers were presented 
throughout. The next stage, biconditional training (BCT), began with illumination of 
the house light. A head entry within 20 s resulted in both levers being presented 
but only one lever was active. The active lever was randomly assigned to each rat 
using an internal random number generator. Assignments are detailed in table 1. A 
correct response within 10 s on the active lever resulted in delivery of a food pellet. 
After a correct or incorrect response, the levers were retracted and the house light 
turned off. The house light was then turned on again and the cycle repeated. If no 
head entry was made within 20 s or no lever press in 10 s, this was counted as 
either head omissions or lever omissions, respectively. During each trial, the lever 
lights were also randomly presented but they gave no indication to which lever was 
active. This was for the possibility of utilising the program in future for other 
cognitive tasks such as a set shifting task. Each session lasted either 30 min or 100 
trials, whichever came first. Each rat had one training session per day. The BCT 
stage lasted 3 days, and only rats reaching criterion at the end of the third day, 
>70% correct responding and <30% omissions, went onto the reversal stage. The 
reversal program was the same as the BCT program for each rat but the previously 
inactive lever was now active and the previously active lever became inactive. Each 
session lasted either 30 min or 100 trials and each rat had one session per day. The 
reversal stage also lasted 3 days (2 days retention after the reversal day), after 
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which all rats went onto the final reversal stage. Here, the active lever was the 
original active lever i.e. the same as in BCT. 
Test Phase 
Day THURS FRI !MON TUE !WED THU I FRI I MON TUE WED! THU FRI MON! TUE 
Stage Magazine FRl FR3 BCT Reversal 1 Retention Reversal 2 Retention 
Figure 2: Reversal learning training procedure for Experiment 1: Effect of 
Methylazoxymethanol Acetate (MAM) treatment on Reversal Learning 
Performance. 
3.2.2 Experiment 2: Effect of mGluS PAM on 
Methylazoxymethanol Acetate (MAM) treated rats in 
Reversal Learning 
3.2.2a Subjects 
Animals were prepared as previously described in Chapter 2. 
48 Male, Sprague Dawley (Crl:CD(SD) (SD), Charles River, Kent) aged 12 weeks at 
the start of the experiment were used and the details are as in 3.2'lA' Pup 
information is shown in table 2 and a timeline of studies is shown in figure 3. 
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Day 1 21 34 83 
Birth Weaning Juvenile Adult 
I I 
Juvenile Adult brain Reversal 
brain weights Learning 
Figure 3: Timeline of events and studies performed for Experiment 2: Effect of 
mGluS PAM on Methylazoxymethanol Acetate (MAM) treated rats in Reversal 
Learning. 
3.2.2b Reversal Learning 
3.2.2b(i) Apparatus 
Apparatus remained the same as in 3.2'lA' 
3.2.2b(ii) Reversal Learning Procedure 
Reversal Learning remained the same as in 3.2.1b. However, in this case, the 
subjects were divided into 3 groups, vehicle (MAM n = 10, SHAM n = 8), mGluS 
before Reversal 1 (MAM n = 7, SHAM n = 8), and mGluS after Reversal 1 (MAM n = 
7, SHAM n = 8). All assignments are shown in table 2. On reversal 1 day, subjects 
were orally administered with either vehicle or mGluS either 30 mins before being 
put into the operant chamber or immediately after they finished the 30min 
procedure (figure 4). 
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3.2.2b(iii) Drugs 
LSN2814617 (Lilly, UK), 1 mg/kg, 1 mg/ml accounting for salt weight in 1% CMC, 
0.25% tween, 0.05% antifoam administered orally either 30 min before reversal 1 
or directly after reversal!. 
Test Phase 
Day THURS FRI IMaN TUE IWED THU I FRI I MaN TUE WED I THU FRI MaNI TUE 
Stage Magazine FRl FR3 BCT Reversal 1 Retention Reversal 2 Retention 
Dosing sefor:! 
Reversal 1 
tDosing after 
Reversal 1 
Figure 4: Reversal Learning training and dosing procedure for Experiment 2: Effect 
of mGlu5 PAM on Methylazoxymethanol Acetate (MAM) treated rats in Reversal 
Learning. 
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Table 2: Detail of pup treatment groups and lever assignment for Experiment 2: 
Effect of mGluS PAM on Methylazoxymethanol Acetate (MAM) treated rats in 
Reversal Learning. 
Number Pup TaQ Group CaQe Active Lever mGlu5 Treatment 
1 NN222 2407985 RiQht After Rev1 
2 AA155 2450817 SHAM E17 1 Left Before Rev1 3 EE180 2409630 Left Before Rev1 
4 FF184 2408999 Left Before Rev1 
5 FF187 2407398 RiQht After Rev1 
6 U129 2410268 SHAM E17 7 Left Before Rev1 7 A2 2409324 Left Before Rev1 
8 B8 2409600 Left Before Rev1 
9 N86 2448551 Left After Rev1 
10 C17 2333806 MAM E17 9 RiQht Vehicle 11 0105 2402719 Left Before Rev1 
12 KK215 2410162 Left Vehicle 
13 F43 2407848 Riaht Before Rev1 
14 JJ205 2402462 MAM E17 11 Riaht Before Rev1 15 KK212 2408884 RiQht Vehicle 
16 R113 2409576 Left After Rev1 
17 Y144 2410285 Right Vehicle 
18 B10 2408971 SHAM E17 14 Left Vehicle 19 LL216 2407645 Left After Rev1 
20 U128 2410204 Riaht Vehicle 
21 161 2409358 Right Vehicle 
22 GG189 2399045 SHAM E17 15 Riaht After Rev1 23 K77 2451790 Riaht After Rev1 
24 EE174 2450109 RiQht Vehicle 
25 NN224 2410335 RiQht After Rev1 
26 FF185 2449966 SHAM E17 18 Riaht Before Rev1 27 M85 2453466 RiQht Before Rev1 
28 X138 2403963 Left After Rev1 
29 JJ204 2404041 Left Vehicle 
30 H55 2399546 MAM E17 24 Left Vehicle 31 KK214 2407917 Riaht Vehicle 
32 E35 2409170 Left Vehicle 
33 CC164 2451702 Riaht Before Rev1 
34 H57 2409336 MAM E17 28 Riaht Before Rev1 35 N87 2452068 Right After Rev1 
36 F39 2407565 Riaht Vehicle 
37 P99 2399451 Left Before Rev1 
38 N88 2451506 MAM E17 31 Left After Rev1 39 JJ203 2402546 Left Vehicle 
40 F37 2399078 Left Vehicle 
41 L81 2449219 Left Vehicle 
42 LL218 2403496 SHAM E17 33 Left Vehicle 43 EE175 2408852 Riaht After Rev1 
44 G50 2402914 Left Vehicle 
45 0107 2409815 Riaht After Rev1 
46 E29 2407789 MAM E17 37 Right After Rev1 47 T120 2398995 Riaht Before Rev1 
48 H58 2410132 Left After Rev1 
94 
Chapter 3: Spatial Reversal Learning 
3.2.3 Experiment 3: Effect of mGluS PAM on 
Methylazoxymethanol Acetate (MAM) treated rats in 
Reversal Learning 
3.2.3a Subjects 
Animals were prepared as previously described in Chapter 2. 
72 Male, Sprague Oawley (Crl:CO(SO) (SO), Charles River, Kent) aged 12 weeks at 
the start of the experiment were used and the details are as in 3.2.1A. Pup 
information is shown in table 3 and a timeline of studies is shown in figure 5. 
Day 1 21 34 83 
Birth Weaning Juvenile Adult 
I I 
Juvenile Adult brain Reversal 
brain weights learning 
Figure 5: Timeline of events and studies performed for Experiment 3: Effect of 
mGlu5 PAM on Methylazoxymethanol Acetate (MAM) treated rats in Reversal 
Learning 
3.2.3b Reversal Learning 
S.2.3b(i) Apparatus 
Apparatus remained the same as in 3.2.1A. 
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Table 3: Detail of pup treatment groups and lever assignment for Experiment 3: Effect of mGluS PAM on Methylazoxymethanol Acetate (MAM) 
treated rats in Reversal Learning. Those highlighted in yellow were excluded from the final results as they were born a day too late. 
Rat Pup Tag Group Cage Lever mGlu5 Treatment Birth Rat Pup Tag Group Cage Lever mGlu5 Treatment Birth 
1 153 2556711 MAM 3 Right Before Rev2 28 37 C13 2555117 SHAM 29 Left Before Rev1 28 
2 L67 2555620 MAM 3 Right Before Rev1 28 38 J57 2553016 SHAM 29 Left Before Rev1 28 
3 S124 2575301 MAM 3 Left Vehicle 29 39 X149 2574498 SHAM 29 Right Vehicle 28 
4 JJ206 2575035 MAM 3 Right Before Rev1 28 40 GG189 2575597 SHAM 29 Left Before Rev2 28 
5 B12 2553107 MAM 4 Right Before Rev1 28 41 B5 2551583 MAM 32 Left Before Rev1 28 
6 M75 2553351 MAM 4 Right Vehicle 28 42 K61 2558280 MAM 32 Left Before Rev2 28 
7 T129 2573910 MAM 4 Right Before Rev2 28 43 Q109 2558896 MAM 32 Right Before Rev1 29 
8 JJ211 2571603 MAM 4 Right Before Rev2 28 44 JJ205 2578688 MAM 32 Left Before Rev1 28 
9 C16 2555759 SHAM 5 Right Before Rev2 28 45 G39 2552670 SHAM 35 Left Before Rev1 29 
10 R115 2556998 SHAM 5 Right Before Rev1 28 46 N89 2555781 SHAM 35 Right Vehicle 28 
11 CC168 2579668 SHAM 5 Left NT 29 47 AA162 2571607 SHAM 35 Right Before Rev2 28 
12 N90 2559196 SHAM 5 Left Before Rev1 28 48 EE180 2563285 SHAM 35 Right Vehicle 28 
13 022 2555696 SHAM 10 Left Before Rev2 28 49 021 2556708 SHAM 37 Left Vehicle 28 
14 V138 2574984 SHAM 10 Right Before Rev1 28 50 J56 2553853 SHAM 37 Right Vehicle 28 
15 CC169 2570311 SHAM 10 Right Vehicle 29 51 AA161 2574764 SHAM 37 Left Before Rev1 28 
16 11200 2575687 SHAM 10 Right Before Rev2 28 52 GG188 2552408 SHAM 37 Right Before Rev2 28 
17 E26 2555607 SHAM 12 Left Before Rev1 29 53 F33 2552948 MAM 41 Left Before Rev2 28 
18 R119 2579816 SHAM 12 Left Before Rev2 28 54 K65 2557582 MAM 41 Right Vehicle 28 
19 AA164 2555766 SHAM 12 Right Vehicle 28 55 U134 2575955 MAM 41 Right Before Rev1 28 
20 EE177 2576673 SHAM 12 Left Vehicle 28 56 HH193 2575298 MAM 41 Left Before Rev2 29 
21 H44 2556782 MAM 17 Right Before Rev2 28 57 B7 2559046 MAM 42 Left Vehicle 28 
22 094 2571855 MAM 17 Right Vehicle 28 58 M83 2557883 MAM 42 Left Before Rev2 28 
23 Q110 2552085 MAM 17 Right Vehicle 29 59 S125 2574062 MAM 42 Left Vehicle 29 
24 00174 2574137 MAM 17 Left Before Rev2 28 60 W146 2570960 MAM 42 Right Before Rev1 29 
25 G42 2555849 SHAM 21 Right Vehicle 29 61 E23 2558367 SHAM 46 Right Before Rev1 29 
26 N85 2559629 SHAM 21 Left Before Rev2 28 62 R120 2579006 SHAM 46 Left Before Rev2 28 
27 X148 2575439 SHAM 21 Left Before Rev1 28 63 V143 2573364 SHAM 46 Right Before Rev1 28 
28 FF187 2571714 SHAM 21 Left Before Rev2 29 64 11201 2572363 SHAM 46 Right Before Rev2 28 
29 E25 2557254 SHAM 25 Right Vehicle 29 65 F36 2554420 MAM 47 Right Before Rev2 28 
30 J59 2557017 SHAM 25 Left Before Rev1 28 66 K64 2555509 MAM 47 Left Vehicle 28 
31 BB166 2571094 SHAM 25 Right Vehicle 28 67 T132 2573061 MAM 47 Right Before Rev1 28 
32 11203 2574367 SHAM 25 Left Before Rev2 28 68 HH196 2576101 MAM 47 Right Before Rev2 29 
33 F31 2558972 MAM 26 Right Before Rev1 28 69 B6 2556674 MAM 48 Right Before Rev1 28 
34 096 2572130 MAM 26 Right Vehicle 28 70 L72 2555437 MAM 48 Left Before Rev2 28 
35 P107 2574643 MAM 26 Right Before Rev1 28 71 U133 2573628 MAM 48 Left Vehicle 28 
36 00173 2573144 MAM 26 Left Vehicle 28 72 JJ208 2553470 MAM 48 Right NT 28 
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3.2.3b(ii) Reversal Learning Procedure 
Reversal Learning remained mainly the same as in 3.2.2b but a third reversal was 
introduced to test of the MAM deficit seen in reversal 2 remained and if treatment 
with the mGlu5 PAM could attenuate the deficit. Subjects were originally divided 
into 3 groups, vehicle (MAM n = 11, SHAM n = 11), mGlu5 before Reversal 1 (MAM 
n = 12, SHAM n = 12), and mGlu5 before Reversal 2 (MAM n = 12, SHAM n = 12) but 
as it was found that birth date might be an important factor, all the rats that were 
born a day too late (29 th ) were excluded. The resulting n numbers were: vehicle 
(MAM n = 8, SHAM n = 8), mGluS before Reversal 1 (MAM n = 10, SHAM n = 9), and 
mGlu5 before Reversal 2 (MAM n = 10, SHAM n = 11). 
Test Phase 
Day rHURS FRI IMON rUE IWED rHU I FRI IMON rUE WED I rHU FRI MONI rUE WED rHU I FRI 
Stage Magazine FRl FR3 BCT Rev 1 Retention Rev 2 Retention Rev 3 Retention 
Dosing .1 
Before Rev 1 
Dosing .1 
Before Rev 2 
Figure 6: Reversal Learning training and dosing procedure for Experiment 3: Effect 
of mGlu5 PAM on Methylazoxymethanol Acetate (MAM) treated rats in Reversal 
Learning (repeat) 
3.2.3b(iii) Drugs 
LSN2814617 (Lilly, UK), 1 mg/kg, 1 mg/ml accounting for salt weight in 1% CMC, 
0.25% tween, 0.05% antifoam administered orally either 30 min before reversal 1 
or 30 min before reversal 2. 
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3.2.4 Statistical Analysis 
All statistical analysis were calculated using STATISTICA v.7 and all data are 
expressed as mean ± standard error of the mean (s.e.m). In general, data was 
analysed using two-way analysis of variance, followed where appropriate by 
planned comparisons (univariate test of significance) with between subject factors 
of group (MAM; SHAM) vs. treatment (veh; mGluS). In the case of significant 
interactions, these were further submitted to analyses of simple effects and if 
appropriate to planned comparisons. Brain and body weight was analysed 
separately for each strain using two-way analyses of variance with between subject 
factors of group (MAM; SHAM). In all cases, P<O.OS indicated significance. 
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3.3 Results 
3.3.1 Experiment 1: Effect of Methylazoxymethanol 
Acetate (MAM) treatment on Reversal Learning 
Performance 
3.3.1a Brain and Body Weights. 
Repeated measures ANOVA showed no significant difference in the body weight 
gain (Figure 7a) between MAM and SHAM treated rats (F(3,40) = 0.997, p>O.l). There 
was an effect of treatment on brain weights in that MAM brains were significantly 
smaller than those of SHAM rats (F(l,lO) = 0.098, p<O.OOl)(Figure 7b). 
A Juvenile Body Weight 
400 
300 
1: 200 0'1 
~ ~
100 
0-'------
MAM SHAM 
Group 
2.5 
2.0 
:§ 1.5 
1: 
0'1 
~ ~ 1.0 
0.5 
B Juvenile Brain Weight 
*** 
0.0.1--
MAM SHAM 
Group 
Figure 7: (a) Body weights and (b) brain weights in juvenile rats treated with 
MAM on E17 
Effect of MAM treatment on day E17 on (a) body weights (g) and (b) brain weights 
(g) in juvenile rats (n = 8 per group). Data are presented as mean ± standard error of 
the mean. Significant differences are indicated on the figure as follows: *** 
P<O.OOl. 
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3.3.1b Reversal Learning Task 
Repeated measures ANOVA showed no significant difference in the acquisition 
(BCT) phase of the reversal task over the 3 days between MAM and SHAM treated 
rats (F(1,39) = 0.001, p>O.l). There was however a deficit in performance in reversal 1 
(F(1,39) = 13.675, p<O.OOl) and reversal 2 (F(1,39) = 5.675, p<0.05) where the 
percentage accuracy was significantly lower in the MAM treated animals compared 
to the SHAMs (figure 8). 
Total Accuracy 
BCT Reversal 1 Reversal 2 
120 
-
MAM E17 
>- 100 c:::::::::J SHAM E17 U 80 ca 
* ... 
:::s 60 u 
* u 
c( 40 
'#. 20 
0 
Baseline Reversal 1 Reversal 2 
Group 
Figure 8: Performance of adult rats treated with MAM on E17 on the reversal 
learning task 
Effect of MAM treatment on E17 in adult rats on percentage accuracy in reversal 
learning. Data are presented as mean ± standard error of the mean (n = 15 per 
group). Significant differences are indicated on the figure as follows:* P<0.05. 
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3.3.2 Experiment 2: Effect of mGluS PAM on 
Methylazoxymethanol Acetate {MAM} treated rats in 
Reversal Learning 
3.3.2a Brain and Body Weights. 
Repeated measures ANOVA showed no significant difference in the body weight 
gain (Figure 9a,b) between MAM and SHAM treated rats (F(3,4o) = 0.997, p>O.l). 
There was an effect of treatment (F(1,28) = 71.97, p<O.OOl) and age (F(1,28) = 414.11, 
p<O.OOl) on brain weights (Figure 10a,b). 
A Juvenile B Adult 
400 
en 300 
-
-.c . ~ ~ 200 
~ ~
100 
o 
MAM E17 SHAM E17 MAM E17 SHAM E17 
Group 
Figure 9: Body weights in (a) juvenile and (b) adult rats treated with MAM on E17 
Effect of MAM treatment on days E17 in (a) juvenile and (b) adult rats on body 
weights (g) (n = 8 per group). Data are presented as mean ± standard error of the 
mean. 
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Figure 10: Brain weights in (a) juvenile and (b) adult rats treated with MAM on 
E17 
Effect of MAM treatment on days E17 in (a) juvenile and (b) adult rats on brain 
weights (g) (n = 8 per group). Data are presented as mean ± standard error of the 
mean. Significant differences are indicated on the figure as follows: *** P<O.OO1. 
3.3.2b Reversal Learning Task 
Repeated measures ANOVA showed no significant difference in the acquisition of 
the reversal task over the 3 days between MAM and SHAM treated rats (F(2,122) = 
1.92, p>0.1). There was also no significant deficit in performance at reversal 1 
(F(l,l11) = 0.143, p>O.5) in the MAM treated rats, however there was a significant 
deficit at reversal 2 where the percentage accuracy of MAM treated rats was 
significantly lower than the SHAM rats (F(1,111) = 5.333, p<0.05)(Figure 11A,b). 
Treatment with the mGlu5 PAM attenuated this deficit as there was no significant 
difference the MAM and SHAM rats treated with the PAM either before or after 
Reversal 1 (Figure 11A). This is further highlighted by figure llb which shows a 
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significant difference between MAM rats treated with vehicle and those treated 
with the mGluS PAM but no significant difference between the same SHAM groups. 
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Figure 11: Effect of mGluS PAM treatment on performance on the (a) reversal 
learning task and the (b) reversal 2 phase of the task in adult MAM E17 treated rats. 
Effect of 1 mg/kg mGlu5 PAM on percentage accuracy in the (a) reve rsal learning and 
(b) the reversal 2 phase of the task in MAM E17 treated rats. N numbers are as 
follows: vehicle (MAM = 10, SHAM = 8), mGlu5 before Reversal 1 (M AM = 7, SHAM = 
8), and mGlu5 after Reversal 1 (MAM = 7, SHAM = 8). Data are presented as mean ± 
standard error of the mean. Significant differences are indicated on the figure as 
follows: * P<0.05; ** P<O.Ol. 
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3.3.3 Experiment 3: Effect of mGluS PAM on 
Methylazoxymethanol Acetate (MAM) treated rats in 
Reversal Learning (repeat) 
3.3.3a Brain and Body Weights. 
Repeated measures ANOVA showed no significant difference in the body weight 
gain (Figure 12a,b) between MAM and SHAM treated rats (F(2.314) = 0.46, p>O.s). 
There was an effect of treatment on brain weights (F(l.21) = 57.78, p<O.OOl)(Figure 
13a,b). 
A Juvenile B Adult 
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Figure 12: Body weights in (a) juvenile and (b) adult rats treated with MAM on 
E17 
Effect of MAM treatment on days E17 in (a) juvenile and (b) adult rats on body 
weights (g) (n = 8 per group). Data are presented as mean ± standard error of the 
mean. 
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Figure 13: Brain weights in (a) juvenile and (b) adult rats treated with MAM on 
E17 
Effect of MAM treatment on days E17 in (a) juvenile and (b) adult rats on brain 
weights (g) (n = 8 per group). Data are presented as mean ± standard error of the 
mean. Significant differences are indicated on the figure as follows: *** P<O.OO1. 
3.3.3b Reversal Learning Task 
Repeated measures ANOVA showed no significant difference in the acquisition of 
the reversal task over the 3 days between MAM and SHAM treated rats (F(1,216) = 
1.7, p>O.l). There was also no significant deficit in performance at reversal 1 in any 
of the treatment groups (F(1,147) = 1.613, p>O.l) in the MAM treated rats, however 
there was a significant deficit at reversal 2 (F(1,147) = 4.345, p<O.05) where the 
vehicle treated MAM rats performed significantly lower than the SHAM rats. 
Treatment with the mGlu5 PAM on the day of reversal 1 significantly attenuated 
this deficit as shown by Figure 14a and b. The group that received the mGlu5 PAM 
on the day of reversal 2 instead of reversal 1 showed a trend towards MAMs 
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performing lower than SHAMs (p = 0.07) (Figure 14a; Reversal 2). This same group 
did not show improved performance on reversal 3 whereas the MAM group that 
received treatment on reversal 1 were still performing at the higher level of the 
SHAMs. 
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Figure 14: Effect of mGluS PAM treatment on performance on the (a) reversal 
learning task and the (b) reversal 2 phase of the task in adult rats treated with MAM 
on El70 
Effect of 1 mg/kg mGluS PAM on percentage accuracy in the (a) reversal learning and 
(b) the reversal 2 phase of the task in MAM E17 t reated rats. N numbers are as 
follows: vehicle (MAM = 8, SHAM = 8), mGluS before Reversal 1 (MAM = 10, SHAM = 
9), and mGluS before Reversal 2 (MAM = 10, SHAM = l1)Data are presented as mean 
± standard error of the mean. Significant differences are indicated on the figure as 
follows: * P<O.OS; ** P<O.Ol; *** P<O.OOl. 
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3.4 Discussion 
This study demonstrates that the novel mGlu5 PAM LSN2814617 attenuates 
reversal learning deficits in the MAM E17 model of schizophrenia, as measured by 
the rodent spatial reversal learning task. Overall, these findings are noteworthy for 
their demonstration of a cognitive enhancing effect of LSN2814617 in a test of 
fronto-executive function in an animal model of schizophrenia. As shown in 
previous chapters, there was no effect of MAM treatment on body weight and 
MAM treatment produced a reduction in brain weight in both juvenile and adult 
brains, indicating successful MAM treatment. 
All three studies within this chapter showed a consistent deficit in reversal learning 
in the MAM treated rats. Effective performance in the reversal-learning task 
requires intact cognitive ability; thus animals are required to demonstrate 
flexibility, attention, motivation, and ability to suppress a previously learned 
response and implement a new one (Jones et 01., 1991). The MAM E17 model has 
been shown previously to produce a wide variety of cognitive impairments, 
including impaired reversal learning and attentional set-shifting (Moore et 01., 2006; 
Featherstone et 01., 2007) although these were not in an operant reversal learning 
task such as this one. The reversal-learning task has been highlighted by the 
MATRICS initiative as a test of reasoning and problem solving i.e. executive 
function. Similar tests in schizophrenia patients, such as the Wisconsin Card Sorting 
Test, require intact functioning of the PFC (Deicken et 01., 1995; Dias et aI., 1997). It 
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has been shown more specifically that lesions of the orbital prefrontal cortex impair 
reversal learning (McAlonan and Brown., 2003; Tait and Brown., 2007). Through 
lesion and electrophysiological studies in rats and monkeys, reversal learning is 
known to be controlled by a neural network that include several regions of 
importance in schizophrenia, such as the hippocampus, amygdala, medial striatum, 
orbitofrontal (OFC) and medial prefrontal cortex (mPFC) (Clarke et 01., 2008; Dias et 
01., 1996; Chudasama and Robbins., 2003; McAlonan and Brown., 2003) as 
discussed in the introduction. As shown in chapter 2, MAM treated rats have 
decreased prefrontal cortex thickness compared to SHAM rats which could be an 
indication that the orbital and/or medial PFC of these rats is altered. As discussed in 
chapter 1, MAM is a CNS specific mitotoxin and therefore affects cell division. 
Dosing MAM on E17 coincides with the cell division of the neurones migrating to 
the hippocampus and prefrontal cortex. Indeed, MAM-treated rats have been 
shown to exhibit morphological changes in the PFC (Featherstone et 01., 2007; 
Gourevitch et 01., 2004). A loss of parvulbumin containing internurones in the PFC 
has also been shown in MAM treated animals (Lodge et 01., 2009) as well as in 
schizophrenic patients (Lewis and Moghaddam., 2006). 
Impaired reversal learning has also recently been highlighted to occur reliably in 
schizophrenia showing some translational validity of the model. Leeson et 01., 
(2009) found in a large group of first episode schizophrenic patients exhibited small 
but consistent and highly significant deficits in reversal learning. These deficits in 
reversal learning, unlike those found in set-shifting, were unrelated to general 
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intelligence and correlated significantly with the disorganization syndrome, 
especially of positive formal thought disorder, which presumably interferes with 
cognitive function and has been shown to be related to reductions in OFC volume 
(Nakamura et al., 2008). Similarly, reversal learning impairments have been 
observed in schizophrenics in the context of changes in frontostriatal activation 
(Murray et al., 2008). 
Gastambide et al., (2012) have shown that the reversal learning deficit seen in 
MAM-treated rats is a specific form, namely in perseverative responding (where the 
rat continues to choose the previously correct stimulus). Interestingly, 
perseverative behaviour is widely observed in patients with schizophrenia 
undertaking tasks such as the Winconsin Card Sorting test (Perry and Braff, 1998; 
Pantelis et al., 1999; Liddle., 2000) and schizophrenic patients with a hippocampal 
lesion have also been shown to commit significantly more perseverative errors 
when performing on the WCST, than subjects with frontal lobe damage (Corcoran 
and Upton., 1993). Such evidence supports the notion that reversal learning may be 
a viable translational element of schizophrenic cognitive deficits that can be studied 
in both rodents and humans. 
There were however some discrepancies with regards to the reversal learning 
deficits. The deficits were seen in reversal 1 and 2 in the first study but only in 
reversal 2 in the second and third studies. In the reversal paradigm of the Morris 
Water Maze task, MAM-treated rats performed significantly worse than controls on 
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days 2 and 3 of testing. On the last day, however, they performed as well as the 
controls (Flagstad et al., 2005). In set-shifting task that contains three reversals, 
MAM rats have been shown to have deficits in the first and third reversals in some 
instances (Featherstone et al., 2007), and in the first and second reversal in others 
(Gastambide et al., 2012). Orbital frontal lesions, however, routinely cause an 
impairment in initial reversal learning in an operant reversal learning task which 
then improves across reversals (Boulougouris et al., 2007). 
mGlus receptors are expressed in key brain regions for cognition, including 
hippocampus, amygdala, striatum and prefrontal cortex (Shigemoto et al., 1993; 
Romano et al., 1995). Modulation of mGlus can therefore alter a wide range of 
cognitive functions in rodents including working memory, attention and cognitive 
flexibility (Kinney et al., 2003; Homayoun et al., 2004; Manahan-Vaughan and 
Braunewell., 2005; Semenova and Markou, 2007; Ayala et al., 2009; Xu et al., 2009; 
Homayoun and Moghaddam, 2010). The findings' from the current study 
demonstrate that administration of the mGlus PAM LSN2814617 can improve the 
performance of MAM treated rats in reversal learning. However, the underlying 
mechanism of this remains unclear. Gastambide et al., (2012) assessed the regional 
effects of MAM on the expression of mGlus receptors using immunohistochemical 
techniques, as well as the expression of parvalbumin (PV)-containing GABAergic 
interneurons known to be implicated in the neuropathology of schizophrenia 
(Lewis., 2000). They found reductions of PV and mGlus expression in the MAM 
treated rats in both the orbitofrontal and medial prefrontal cortex, which also 
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mediate reversal learning and extra-dimensional set-shifting. mGluS receptors are 
key postsynaptic signalling partners of NMDA receptors (Marino and Conn., 2002). 
Activation of mGluS may therefore potentiate the function of NMDA receptors 
within the reversal learning 'network' and as a result, restore plasticity mechanisms 
which have been reported to be disrupted in the model (Moore et 01., 2006; Lodge 
et 01., 2009; Sanderson et 01., 2011). While there are no published reports of down-
regulation of mGluS receptors in schizophrenia to date, such a finding would be 
consistent with the hypoglutamatergic theory of the disorder. 
Overall, the present data suggest that mGluS potentiation may have beneficial 
effects in the treatment of certain cognitive impairments associated with 
schizophrenia. The efficacy of LSN2814617 in this reversal learning model is 
therefore of particular importance for demonstrating a role for positive modulation 
of mGluS receptors in alleviating cognitive deficits in schizophrenia. Further studies 
are needed to test the mGluS effects in other memory and executive functions, 
such as working memory. However, the present findings do show face and 
construct validity and also indicate the predictive validity of the MAM E17 model 
for testing new drugs that may reverse the specific cognitive deficits seen in 
schizophrenia. 
113 
Chapter 4: Fear Conditioning 
Chapter 4: Fear Conditioning 
4.1 Introduction 
One of the behavioural deficits that has consistently been observed -in 
schizophrenia is impaired emotional learning and memory. It is mediated by several 
discrete neurological regions and requires the interaction of several systems 
(McGaugh., 2004; Phelps., 2004). Specifically, data indicate a deficit in the impact of 
emotion on memory (Hamann et al., 1999; Gur et al., 2002; Kring and Caponigro., 
2010). In non-schizophrenic populations, neuroimaging studies have demonstrated 
that amygdala activation is positively correlated with hippocampal activity and 
subsequent memory while viewing emotional scenes (Hall et al., 2007, Hamann et 
al., 1999; Dolcos et al., 2004). Patients with schizophrenia have been shown to 
display a reduction in amygdala activation when viewing emotional faces and 
reduced activation in the hippocampus during episodic memory tasks (Hall et al., 
2007; Gur et al., 2002; Achim and Lepage., 2005). These findings not only indicate a 
change in emotional processing, but may also represent an alteration in 
connectivity between the amygdala and hippocampus. 
Pavlovian or classical fear conditioning is recognised as a model system to 
investigate the neurobiological mechanisms of learning and memory in the 
mammalian brain and to understand the basis of fear-related disorders in humans. 
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Fear conditioning is a behavioural task where an association is made between a 
neutral auditory or visual stimulus (the conditioned stimulus, CS) and an aversive 
unconditioned stimulus (US) such as a foot shock. Following the CS-US paired 
training the animal is then presented with the CS alone and since it is associated 
with the US it evokes a conditioned fear response (CR), characterised by freezing 
behaviour in rodents, autonomic nervous system responses (increase in blood 
pressure and heart rate), and neuroendocrine responses (release of hormones from 
the pituitary and adrenal glands). 
In a typical auditory fear conditioning paradigm, there are three distinct phases: the 
habituation phase where the rat is left in the chamber and no stimuli are presented, 
the conditioning phase where the tone conditioned stimulus (CS) is paired with the 
footshock unconditioned stimulus (US). The third phase is the extinction or test 
phase. Here the CS is presented in the absence of the US and typically, the rat 
exhibits freezing responses to the CS during this phase. This is known as cued fear 
conditioning, in which the training protocol produces an association between the 
CS and the US. The association can be quantified based on the fear response 
(freezing) to the CS (cued fear) and serves as a measure of how well the animal 
learned an association. In addition, animals also learn a quantifiable association 
between the US and the environment in which the training took place, this is known 
as contextual fear conditioning. 
115 
Chapter 4: Fear Conditioning 
An advantage of this task is that alterations in the training protocol have been 
demonstrated to recruit differential involvement of specific neurological regions in 
order to learn the association. In standard delay cue contextual fear procedures, 
when the CS and US overlap in time and co-terminate, the cued fear component 
requires amygdala function (Phillips and LeDoux., 1992; LeDoux., 2003) and 
contextual fear conditioning depends not only on the amygdala but also on the 
hippocampus. As the amygdala is crucial for the formation of the association 
between the CS and the US it creates the link between the hippocampal 
representation of the context and the aversive shock (US) (LeDoux., 2000; Phillips 
and LeDoux., 1992; Chen at aI., 1996; Logue et 01., 1997; Holland and Bouton., 
1999). A variation known as trace conditioning modifies this task by inserting a 
temporal gap between the cessation of the CS and the onset of the US (Kinney et 
01., 2002). The animal therefore has to maintain a memory 'trace' of the 
conditioned stimulus to associate it with the unconditioned stimulus (Solomon and 
Schaaf et 01., 1986). The insertion of the interval between the CS and US has been 
demonstrated to make the association more difficult, as additional training trials 
are required for equivalent learning (Kinney et 01., 2002; Beylin et 01., 2001). 
Further, data indicate that not only does the task become more difficult, but lesion 
studies demonstrate the trace cued fear association is also dependent on both the 
hippocampus and amygdala (Kinney et 01., 2002; Sutherland and McDonald., 1990; 
McEchron et 01., 1998). Disruption of protein synthesis in the amygdala immediately 
following trace conditioning has been shown to impair the consolidation of cue and 
context memories (Kwapis et 01., 2011). Several studies have also demonstrated a 
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role for a differential role of the dorsal (DH) and ventral (VH) hippocampus (Yoon 
and Otto., 2007; Czerniawski et al., 2009; Esclassan et al., 2009) in the acquisition of 
trace fear conditioning. Neurotoxic lesions of the whole hippocampus or reversible 
inactivation of the ventral hippocampus impaired both contextual and tone freezing 
in both trace and delay conditioned rats. However, dorsal hippocampal injections 
impaired contextual freezing and trace conditioning, but not delay conditionfng 
(Esclassan et al., 2009). Yoon and Otto (2007) found that both pre- and post-
training lesions of ventral hippocampus impaired the acquisition and expression of 
auditory trace fear conditioning. However, pre-training lesions of the dorsal 
hippocampus had no effect on the acquisition of trace fear conditioning, while post-
training lesions of the dorsal hippocampus dramatically impaired expression during 
subsequent testing. The mPFC has also been implicated in trace fear memory 
processes (Blum et al., 2006; Gilmartin and Helmstetter., 2010) and it has been 
shown that the prelimbic (PL) area of the mPFC is necessary for trace but not delay 
fear conditioning (Gilmartin and Helmstetter., 2010). The dependence on mPFC and 
hippocampus in trace fear conditioning suggests that memory formation may 
require communication between these two regions. The PL mPFC may be important 
for helping to maintain the CS across the trace interval (Gilmartin and McEchron., 
2005) and Gilmartin et al., (2012) hypothesized that communication between the 
mPFC and hippocampus is necessary for the association of the CS and US across this 
interval. They found that unilateral inactivation of the ventral hippocampus or 
amygdala impairs memory, while bilateral inactivation of the PL is required to 
produce a deficit. However, deficits after unilateral inactivation of the ventral 
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hippocampus or amygdala prevented them from determining whether the mPFC 
functionally interacts with the hippocampus but their findings suggest that the 
trace fear network is more integrated than previously thought. 
Once fear conditioning has been learned, it can be very difficult to reverse. 
Nevertheless, fear conditioning and its associated fear responses can be inhibited 
by an active process known as fear extinction. Fear extinction occurs when an 
animal is repeatedly exposed to the CS in the absence of the US which leads to a 
decline in the magnitude of the fear-associated response. Like other forms of 
learning and memory, fear extinction involves encoding, consolidation, retrieval 
and expression stages, which are mediated by different neural mechanisms (Myers 
et al., 2011). Unlike fear conditioning, fear extinction is a labile process that tends 
to reverse over time. For instance, exposure to the CS alone, after the extinction 
process has been established, leads to the reappearance of the CR, a phenomenon 
called reinstatement (Myers et al., 2011). Also, fear conditioning can return if the 
old fear stimuli are presented in a different context from the one in which 
extinction was learned, a process termed renewal (Myers et al., 2011). Though fear-
extinction can suppress the fear-associated response, it does not seem to remove 
the synaptic changes acquired during fear conditioning. Thus, fear extinction 
involves new learning and new synaptic changes in the amygdala (Myers et al., 
2011). Fear-extinction learning and memory process, as well as its modulation by 
context, involves three main components: the amygdala, mPFC, and hippocampus 
(Myers et al., 2011; Quirk and Mueller, 2008). 
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As discussed in Chapter 1, one of the prevailing models of schizophrenia proposes a 
reduction in NMDA receptor function on inhibitory interneurons and the resulting 
disinhibition may give rise to aspects of the disorder. Studies using NMDA receptor 
antagonists such as PCP and ketamine have induced schizophrenia-like behavioural 
deficits in animal model systems as well as changes in inhibitory circuits. Bolton et 
al., (2012) utilized both standard delay and trace cued and contextual fear 
conditioning paradigms to examine if ketamine produces differential effects when 
the task is more difficult and relies on connectivity between specific brain regions. 
Rats administered ketamine displayed no significant deficits in cued or contextual 
fear following the delay conditioning protocol. However, ketamine did produce a 
significant impairment in the more difficult trace conditioning protocol. 
As fear conditioning is present across animal species, where the same primitive 
neural circuits may be involved, it has gained much attention as a useful animal 
model for the investigation of the neurobiological components of learning· and 
stress-related memory (Blair et al., 2001; Rogan et al., 2001), because drugs 
affecting fear conditioning may have potential utility for the treatment of anxiety-
related disorders (Millan and Brocco., 2003). Subtype 5 metabotropic glutamate 
receptors (mGluRS) are abundant in the basal ganglia, amygdala, septum, 
hippocampus, peripheral sensory neurones and dorsal horn of the spinal cord. 
Thus, mGluRS has been implicated in central processes underlying movement 
control, emotion, learning, and nociception. In the last two decades, the role of 
glutamate in fear conditioning and anxiety-related disorders is becoming more 
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recognized. The first evidence for the role of mGluS receptors in fear conditioning 
stems from work using mGluS receptor knockout mice. The knockout mice showed 
impairments in acquisition of fear and deficits in the ability to extinguish contextual 
fear (Lu et al., 1997; Xu et al., 2009). Fear conditioning has also been shown to 
cause an up-regulation of mGluS receptor protein levels in the hippocampus (Riedel 
et al., 2000) and mGluS antagonists disrupt contextual fear conditioning but are 
only effective when applied before conditioning rather than after (Rodrigues et al., 
2002; Jacob et al., 2009; Gravius et al., 2008). With this in mind, the aim of the 
present study was to further investigate the effect of prenatal exposure to MAM on 
El7 in delay and trace conditioning and to see if any deficits could be reversed by 
the same mGluS positive allosteric modulator that was used in the reversal learning 
experiments in the previous chapter. 
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4.2 Methods 
4.2.1 Experiment 1: Delay and Trace Fear Conditioning 
performance in Methylazoxymethanol Acetate (MAM) 
treated animals 
4.2.1a Subjects 
Animals were prepared as previously described in Chapter 2. 
36 (20 MAM; 16 SHAM) male, Sprague Dawley (Crl:CO(SO) (SO), Charles River, Kent) 
aged 12 weeks at the start of the experiment were used. Rats were housed in 
groups of 3 or 4 and had ad libitum access to water but were food restricted to 85% 
of their free feeding weight from 8 weeks of age to stop the rats from increasing in 
weight too quickly. Food restriction was maintained for the entire duration of the 
experiment. The rats had environmental enrichment (Jolly BalisTM, (Lillico) plastic 
tubes and wooden blocks). The animals were maintained on a 12-hour light dark 
cycle with lights on at 7.00. The experiments were conducted during the same part 
of the light phase each day and the timeline is shown in figure 1. All experiments 
were carried out in accordance with the UK Animals (Scientific Procedures) Act 
1986, under Home Office project licence 70/6560 and personal licence 71/17650 
(N. N. Malik). 
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Day 1 21 34 83 
Birth Weaning Juvenile Adult 
I I 
Juvenile Fear 
brain Conditionine: 
Figure 1: Timeline of events and studies performed for Experiment 1: Delay and 
Trace Fear Conditioning performance in Methylazoxymethanol Acetate (MAM) 
treated animals 
4.2.1b Fear Conditioning 
4.2.1b(i) Apparatus 
The operant test chambers (Med Associates; ENV 008) were placed inside sound 
attenuating cubicles (Med Associates; ENV 022MD). Each chamber had two 
aluminium walls and two Perspex walls. A house light (100mA, Med Associates; ENV 
215M) positioned 1.8 cm from the ceiling on one wall, was lit during all the testing 
in these chambers. The floor of the chamber consisted of 19 stainless steel bars 
(diameter 0.48 cm, spaced 1.6 cm apart) through which the shocks were delivered. 
Shocks were generated and delivered by a Med Associates aversive 
stimulator/scrambler module (ENV 414). A video camera was attached to the 
centre of the chamber's ceiling and sent black-and-white images of each 
experimental session to a PC equipped with a digital video capture card (Geovision 
Inc., GV-650), and the session videos were recording using Geovision software 
(Multicam surveillance system, version 8.12). The tone that served as the auditory 
conditioned stimulus (C5) was 90 dB and 2000 Hz, generated by a programmable 
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generator package (Med Associates, ANL 926). Presentation of stimuli and shocks 
was controlled by Med-PC software (version IV, Med Associates). On the test days, 
the context was modified by covering the two clear Perspex walls with opaque 
white Perspex panels fixed with Velcro, by covering the metal grid with black 
Perspex grids, and by introducing a novel odour (vanilla oil) into the waste tray. 
Table 1: Detail of pup treatment groups and lever assignment for Experiment 1: 
Delay and Trace Fear Conditioning performance in Methylazoxymethanol Acetate 
(MAM) treated animals 
Rat PUP Tag Group Cage Program 
1 N85 2391842 MAM 4 Delay 
2 E28 2392234 MAM 4 Trace 
3 N82 2392110 MAM 4 Trace 
4 L70 2391729 MAM 4 Delav 
5 A1 2392809 SHAM 5 Trace 
6 816 2392723 SHAM 5 Trace 
7 026 2394083 MAM 12 Trace 
8 L63 2392172 MAM 12 Delay 
9 J53 2129402 MAM 12 Trace 
10 N83 2391323 MAM 12 Delay 
11 L64 2393063 MAM 14 Delay 
12 024 2393257 MAM 14 Trace 
13 J62 2128688 MAM 14 Delay 
14 N84 2392823 MAM 14 Trace 
15 E31 2391277 MAM 16 Trace 
16 L65 2392122 MAM 16 Delay 
17 J58 2129078 MAM 16 Delay 
18 025 2390773 MAM 16 Trace 
19 815 2392706 SHAM 17 Delay 
20 C19 2390867 SHAM 17 Delav 
21 095 2392153 SHAM 19 Trace 
22 813 2392371 SHAM 19 Delay 
23 A10 2393736 SHAM 19 Delay 
24 F35 2394020 SHAM 19 Trace 
25 P98 2394387 MAM 20 Delay 
26 E30 2393107 MAM 20 Trace 
27 021 2392807 MAM 20 Trace 
28 L66 2394574 MAM 20 Delav 
29 A5 2390978 SHAM 21 Trace 
30 094 2392757 SHAM 21 Delay 
31 814 2390745 SHAM 21 Delay 
32 H47 2128686 SHAM 21 Trace 
33 H42 2392347 SHAM 23 Delay 
34 152 2128751 SHAM 23 Trace 
35 C20 2391058 SHAM 23 Trace 
36 A8 2394554 SHAM 23 Delay 
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Delay Fear Conditioning 
Subjects were divided into 2 groups, Delay (MAM n = 10, SHAM n = 8) and Trace 
(MAM n = 10, SHAM n = 8) and all assignments are shown in table 1. 
On pre exposure day, animals were placed in the operant chamber (training 
context) on the first day and were given 10 27s CS (tone) presentations with a 
random inter-trial interval of between 100-140s (mean of 120s) following a 5 
minute habituation period. On conditioning day approximately 24 hours later, 
animals were again placed into the training context and following a 5min 
habituation period, they were given 10 CS/shock pairs, in which a 0.5s, O.5mA foot 
shock co-terminated with the 27s CS. The next 6 days were extinction sessions 
which were given in the modified context (white Perspex walls, black Perspex grid 
floor and vanilla odour in the waste tray) during which rats were presented with the 
27s CS 10 times without any shocks . 
. Trace Fear Conditioning 
On pre exposure day, animals were placed in the operant chamber (training 
context) on the first day and were given 10 lOs CS (tone) presentations with a 
random inter-trial interval of between 100-140s (mean of 120s) following a 5minute 
habituation period. On conditioning day approximately 24 hours later, animals were 
again placed into the training context and following a 5min habituation period, they 
were given 10 CS/shock pairs, in which a 0.5s, 0.5mA foot shock was given after a 
16.5s trace interval, i.e. the shock was given 16.5s after the end of the CS. On the 
next 6 days, extinction sessions were given in the modified context (white Perspex 
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walls, black Perspex grid floor and vanilla odour in the waste tray) during which rats 
were presented with the lOs CS 10 times without any shocks. 
Delay Tone (lSI: 26 s) 
It 27 S " 
Trace Tone (lSI: 265) 
-lOs --. 
CS I CS 1= 17 s " 
us n US n· 
0.5 s 0.5 s 
Figure 2: A schematic of the conditioning protocol used 
4.2.2 Experiment 2: Effect of mGluS treatment on 
MAM treated rats in Trace and Delay Fear 
Conditioning 
4.2.2a Subjects 
Animals were prepared as previously described in Chapter 2. 
96 (48 MAM; 48 SHAM) male, Sprague Oawley (Crl:CO(SO) (SO), Charles River, Kent) 
aged 12 weeks at the start of the experiment were used (details as in 4.2.1A). The 
timeline of experiments and assignments are shown in figure 3 and table 2, 
respectively. 
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Day 1 21 34 83 
Birth Weaning Juvenile Adult 
I I 
Juvenile Fear 
brain Conditioning 
Figure 3: Timeline of events and studies performed for Experiment 2: Effect of 
mGluS treatment on MAM treated rats in Trace and Delay Fear Conditioning 
4.2.2b Fear Conditioning 
4.2.2b(i) Apparatus 
Apparatus remained the same as in 4.2.1A. 
4.2.2b(ii) Fear Conditioning Procedure 
The procedure remained the same as in 4.2.1b but the rats received a context test 
day following conditioning and then 3 days of extinction. Subjects were divided into 
4 groups, delay vehicle (MAM n = 12, SHAM n = 12), trace vehicle (MAM n = 12, 
SHAM n = 12), delay mGluS (MAM n = 12, SHAM n = 12), and trace mGluS (MAM n 
= 12, SHAM n = 12). All assignments are shown in table2. On the day of 
conditioning, subjects were orally administered with either vehicle or mGluS 30 
mins before being put into the operant chamber. 
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4.2.2b(iii) Drugs 
LSN2814617 (Lilly, UK), 1 mg/kg, 1 mg/ml accounting for salt weight in 1% CMC, 
0.25% tween, 0.05% antifoam administered orally. 
Table 2: Detail of pup treatment groups and lever assignment for Experiment 2: 
Effect of mGlu5 treatment on MAM treated rats in Trace and Delay Fear 
Conditioning 
Rat Pup Tag Group Cage Program Treatment Rat Pup Tao Group Cage Program Treatment 
1 AK227 2393758 SHAM 1 Trace mGlu5 49 P105 2393155 MAM 22 Delay VEH 
2 AL235 2391038 SHAM 1 Delay mGlu5 50 AG199 2393696 MAM 22 Delay mGlu5 
3 D18 2393045 SHAM 1 Delay VEH 51 AC170 2391725 MAM 22 Delay mGlu5 
4 AB167 2393232 SHAM 1 Trace VEH 52 R114 2392162 MAM 22 Trace VEH 
5 S122 2393051 MAM 2 Trace mGlu5 53 AB164 2393185 SHAM 23 Trace mGlu5 
6 K73 2393016 MAM 2 Delay VEH 54 AE188 2392194 SHAM 23 Delay VEH 
7 A2 2391318 MAM 2 Delay mGlu5 55 AI211 2394651 SHAM 23 Trace mGlu5 
8 C15 2390830 MAM 2 Delay mGlu5 56 Y148 2393495 SHAM 23 Delay VEH 
9 0102 2391440 SHAM 5 Trace VEH 57 AJ221 2390649 MAM 24 Delay VEH 
10 AK225 2393167 SHAM 5 Delay VEH 58 R112 2393032 MAM 24 Delay VEH 
11 N92 2391036 SHAM 5 Trace VEH 59 K70 2354455 MAM 24 Trace VEH 
12 AE186 2394190 SHAM 5 Delay mGlu5 60 AD178 2390938 MAM 24 Trace mGlu5 
13 AC176 2390932 MAM 6 Trace mGlu5 61 E26 2392382 SHAM 27 Delay mGlu5 
14 C11 2392585 MAM 6 Trace mGlu5 62 Y146 2392595 SHAM 27 Trace mGlu5 
15 AD179 2392838 MAM 6 Trace VEH 63 153 2392645 SHAM 27 Trace VEH 
16 AH208 2392329 MAM 6 Delay VEH 64 AK223 2391429 SHAM 27 Trace VEH 
17 AB163 2393703 SHAM 7 Trace VEH 65 AH209 2395210 MAM 28 Delay mGlu5 
18 0110 2391890 SHAM 7 Delay mGlu5 66 J62 2345914 MAM 28 Trace VEH 
19 X230 2391482 SHAM 7 Trace mGlu5 67 A5 2394004 MAM 28 Trace mGlu5 
20 F33 2394912 SHAM 7 Delay mGlu5 68 AD182 2391389 MAM 28 Delay VEH 
21 M87 2391603 MAM 8 Trace mGlu5 69 U128 2394069 MAM 32 Trace mGlu5 
22 A9 2391463 MAM 8 Delay mGlu5 70 M83 2395159 MAM 32 Delay VEH 
23 AM237 2390722 MAM 8 Trace VEH 71 V131 2394525 MAM 32 Delay VEH 
24 K74 2393163 MAM 8 Trace mGlu5 72 AC169 2395065 MAM 32 Trace VEH 
25 X140 2394717 SHAM 9 Delay VEH 73 W137 2393276 SHAM 33 Trace VEH 
26 F36 2394087 SHAM 9 Trace mGlu5 74 AN241 2394690 SHAM 33 Delay VEH 
27 G41 2390818 SHAM 9 Trace VEH 75 Z151 2393134 SHAM 33 Trace mGlu5 
28 N91 2390885 SHAM 9 Delay VEH 76 AF196 2393872 SHAM 33 Trace mGlu5 
29 C13 2391963 MAM 10 Trace VEH 77 AJ220 2395238 MAM 34 Trace VEH 
30 R116 2391798 MAM 10 Delay mGlu5 78 K75 2392669 MAM 34 Delay mGlu5 
31 AC177 2353595 MAM 10 Delay mGlu5 79 AH205 2393629 MAM 34 Trace VEH 
32 AH207 2391190 MAM 10 Trace mGlu5 80 P104 2395164 MAM 34 Delay mGlu5 
33 AF191 2393075 SHAM 11 Trace VEH 81 AE189 2390972 SHAM 35 Trace VEH 
34 D21 2393465 SHAM 11 Delay mGlu5 82 0108 2392065 SHAM 35 Delay VEH 
35 AK229 2391713 SHAM 11 Delay mGlu5 83 W135 2391551 SHAM 35 Trace mGlu5 
36 157 2392119 SHAM 11 Delay VEH 84 AI210 2394763 SHAM 35 Delay mGlu5 
37 H47 2392410 SHAM 13 Delay mGlu5 85 AJ215 2392791 MAM 36 Delay mGlu5 
38 E30 2393441 SHAM 13 Trace VEH 86 P103 2394894 MAM 36 Trace mGlu5 
39 AL233 2391835 SHAM 13 Delay mGlu5 87 R115 2394343 MAM 36 Trace mGlu5 
40 F34 2393224 SHAM 13 Delay VEH 88 A1 2392988 MAM 36 Delay VEH 
41 AG202 2391978 MAM 14 Trace VEH 89 V129 2394047 MAM 44 Trace VEH 
42 R117 2394748 MAM 14 Delay VEH 90 A3 2394084 MAM 44 Trace VEH 
43 J61 2393249 MAM 14 Trace mGlu5 91 AG198 2348081 MAM 44 Delay VEH 
44 AC172 2392111 MAM 14 Delay VEH 92 M84 2353025 MAM 44 Delay mGlu5 
45 AB161 2394710 SHAM 15 Delay VEH 93 099 2391022 SHAM 45 Trace mGlu5 
46 D20 2390655 SHAM 15 Trace VEH 94 AB168 2393888 SHAM 45 Delay mGlu5 
47 G44 2395067 SHAM 15 Delay mGlu5 95 N90 2393346 SHAM 45 Trace mGlu5 
48 156 2394412 SHAM 15 Trace mGlu5 96 W136 2393071 SHAM 45 Delay VEH 
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4.2.3 Analysis 
4.2.3a Freezing Scoring 
Videos were recorded for all sessions to be analysed for freezing behaviour in 
Freezescan software (CleverSys Inc.). The recorded videos were run through the 
software off-line and the measures recorded were duration of freezing, percent 
freezing, total motion, and average motion (pixels/second). These data were 
exported in 30s time bins for plotting the % freezing over the whole session 
(including the Smin habituation before the session) on each day. The data was also 
exported in is time bins and the timestamps of when the CSs came on (from 
MedPC data) were found in the motion and freezing data. The average % freezing 
over 10-17s (the last 17s of the CS in the delay program, and the 17s trace interval 
in the trace program) of all 10 CSs on Cond, Extl, Ext2 and Ext3 were calculated 
and plotted for each group. 
4.2.3b Statistical Analysis 
All statistical analysis were calculated using STATISTICA v.9 and all data are 
expressed as mean ± standard error of the mean (s.e.m) In general, data was 
analysed using two-way analysis of variance, followed where appropriate by 
planned comparisons (univariate test of significance) with between subject factors 
of group (MAM; SHAM) vs. treatment (veh;mGluS). In the case of significant 
interactions, these were further submitted to analyses of simple effects and if 
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appropriate to planned comparisons. Brain and body weight was analysed 
separately for each strain using two-way analyses of variance with between subject 
factors of group (MAM; SHAM). In all cases, P<O.OS indicated significance. 
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4.3 Results 
4.3.1 Experiment 1: Effect of Methylazoxymethanol 
Acetate (MAM) treatment on Fear Conditioning 
Performance 
4.3.1a Brain and Body Weights 
Repeated measures ANOVA showed no significant difference in the body weight 
(Figure 4a) between MAM and SHAM treated rats (F(l,lO) = 0.681, p>O.l). There was, 
as expected, a significant effect of MAM treatment on brain weights (F(l,lO) = 
19.170, p<O.Ol)(Figure 4b). 
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Figure 4: (a) Body weights and (b) brain weights in juvenile rats treated with 
MAM on E17 
Effect of MAM treatment on day E17 on (a) body weights (g) and (b) brain weights 
(g) in juvenile rats. Data are presented as mean ± standard error of the mean. (n = 
8 per group). Significant differences are indicated on the figure as follows: ** 
P<O.Ol. 
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4.3.1b Fear Conditioning Task 
4.3.1b(i) Conditioning 
There was an effect of treatment and task type on acquisition of during the 
conditioning day, F(l,320) = 5.632, p<0.05) and (F(l,320) = 11.505, p<O.OOl), 
respectively. However there was no interaction between the two (F(l,320) = 0.836, 
p>O.1. Further planned comparisons on individual CSs 'showed there was no 
significant difference between the MAM and SHAM groups in Delay conditioning. 
There was however a significant effect at CS6 in Trace conditioning in that MAM 
treated rats froze significantly less than SHAM rats with trend effects at CS5, CS7 
and CS8 (Figure 5b). 
Figure 5: Acquisition of freezing behaviour during (a) Delay (b) Trace conditioning 
in adult rats treated with MAM on E17. 
Effect of MAM treatment on day E17 on (a) Delay and (b) Trace conditioning in 
adult rats. Data are presented as mean ± standard error of the mean. (N numbers 
are as follows: delay (MAM = 10, SHAM = 8), trace (MAM = 10, SHAM = 8). 
Significant differences are indicated on the figure as follows:* P<0.05. 
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4.3.1b(ii) Extinction 
Average freezing on Extinction days were analysed in 1s time bins and the mean % 
freezing from CSl-4 was calculated. This was because rats normally start to 
extinguish to the cue after this point as can be seen in figure 6. 
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Figure 6: An example of freezing behaviour during (a) Delay (b) Trace Extinction 
Day 3 in adult rats treated with MAM on E17. 
Effect of MAM treatment on day E17 on (a) Delay and (b) Trace extinction in adult 
rats. Data are presented as mean ± standard error of the mean. (N numbers are as 
follows: delay (MAM = 10, SHAM = 8), trace (MAM = 10, SHAM = 8). 
MAM treatment had no significant effect on freezing on extinction days 1, 4, 5 and 
6, F(1,32) = 0.176, p>O.5) , F(1,32) = 1.198, p>O.l) , F(1,32) = 0.324, p>0.5) and 
(F(1,32) = 0.384, p>O.5) respectively and there was also no interaction between 
treatment*program, F(1,32) = 2.8721, p>0.05) , F(1,32) = 0.657, p>O.l) , F(1,32) = 
0.369, p>O.5) and (F(1,32) = 1.032, p>O.l). 
There was also no significant effect of treatment on days 2 and 3 (F(1,32) = 0.094, 
p>0.5) and F(1,32) = 0.002, p>O.5)) but there was an interaction between 
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treatment and program (fear conditioning type) on both of these days, F(1,32) = 
7.534, p<O.Ol) and F(1,32) = 15.345, p<O.OOl) respectively. 
Further planned comparisons on individual CSs showed significant differences 
between the MAM and SHAM groups in Delay conditioning on extinction day 3 
where MAM animals were freezing significantly more than SHAM rats. Rats ran in 
Trace conditioning had the opposite effect where the MAM treated rats froze 
considerably less than the SHAM rats on extinction days 2 and 3 (Figure 7). 
Extinction 
A Delay B Trace 
100 ** --- MAM 
--0- SHAM 
* 
** 
c:n 
C 80 
'N 
m ~ ~
.. , 60 LL ..... 
~ C J ) )
o (.) 40 c-
ca 
CI) 
:E 20 
0 
Ext 1 Ext 2 Ext 3 Ext 4 Ext 5 Ext 6 Ext 1 Ext 2 Ext 3 Ext 4 Ext 5 Ext 6 
Extinction Day 
Figure 7: Delay and Trace Extinction days 1-6 in adult rats treated with MAM on 
E17. 
Effect of E17 MAM treatment on extinction in Delay and Trace fear conditioning in 
adult rats. Data are presented as mean (CS 1-4) ± standard error of the mean. (N 
numbers are as follows: delay (MAM = 10, SHAM = 8), trace (MAM = 10, SHAM = 8). 
Significant differences are indicated on the figure as follows:* P<0.05; ** P<O.Ol. 
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4.3.2 Experiment 2: Effect of mGluS PAM on 
Methylazoxymethanol Acetate (MAM) treated rats in 
Fear Conditioning 
4.3.2a Brain and Body Weights 
There was no significant difference in the body weight (Figure 8a) between MAM 
and SHAM treated rats (F(1,8) = 2.549, p>O.l). There was an effect of treatment (F(1,8) 
= 32.629, p<O.OOl) on brain weight (Figure 8b). 
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Figure 8: (a) Body weights and (b) brain weights in juvenile rats treated with 
MAMon E17 
Effect of MAM treatment on day E17 on (a) body weights (g) and (b) brain weights 
(g) in juvenile rats. Data are presented as mean ± standard error of the mean (n = 8 
for all groups). Significant differences are indicated on the figure as follows: *** 
P<O.OO1. 
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4.3.2b Fear Conditioning Task 
4.3.2b(i) Conditioning 
There was an effect of treatment and task type on acquisition of during the 
conditioning day, F(3,888) = 4.556, p<O.Ol) and (F(l,888) = 21.148, p<O.OOOl) 
respectively. Further planned comparisons on individual CSs showed there was no 
significant difference between the MAM and SHAM groups in Delay conditioning. 
There was however a significant effect at CS2 in Trace conditioning in that MAM 
treated rats froze significantly less than SHAM rats with and that treatment with 
mGlu5 seemed to increase the freezing back to that of the SHAM groups. 
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Figure 9: Effect of mGluS PAM treatment on performance on (a) Delay and (b) 
Trace fear conditioning in adult rats treated with MAM on El7. 
Effect of 1 mg/kg mGlu5 PAM on percentage freezing in the (a) Delay and (b) Trace 
fear conditioning in MAM E17 treated rats. Data are presented as mean ± standard 
error of the mean (n = 12 for all groups) . Significant differences are indicated on the 
figure as follows : vs . vehicle * P<O.05; vs . mGlu5 # P<O.05. 
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4.3.2b(ii) Context 
MAM treatment had a significant effect on freezing on context day, F(3,88) = 
5.5791, p<O.Ol) but there was no effect of program type or an interaction between 
the two, F(l,88) = 2.383, p>0.05) , F(3,88) = 0.739, p>O.5) respectively. 
Further analysis showed that this treatment effect was specifically on Trace 
conditioning where MAM treated rats froze significantly less that SHAM treated 
rats (Figure lOb) but treatment with the mGlu5 PAM did not ameliorate this deficit 
(Figure 10c). 
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Figure 10: % freezing on Context day in (a) Delay and (b) Trace fear 
conditioning in adult rats treated with MAM on E17. (c) Mean % freezing in 
response to mGluS PAM. 
Effect of MAM treatment on percentage freezing in the (a) Delay and (b) Trace 
fear conditioning in MAM El7 treated rats. (c) Effect of 1 mg/kg mGluS PAM on 
percentage freezing in the Delay and Trace fear conditioning in MAM E17 treated 
rats. Data are presented as mean ± standard error of the mean (n = 12 for all 
groups). Significant differences are indicated on the figure as follows:* P<O.OS. 
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4.3.2b(ii) Extinction 
MAM treatment had no significant effect on freezing on any of the extinction days, 
F(l,88) = 1.083, p>O.l) , F(l,88) = 0.016, p>0.5) , F(l,88) = 0.681, p>0.5) and (F(l,88) 
= 0.110, p>0.5) respectively and there was also no interaction between 
treatment*program, F(3,88) = 0.552, p>0.05) , F(3,88) = 0.982, p>O.l) , F(3,88) = 
0.414, p>O.l) and (F(3,88) = 1.152, p>O.l). 
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Figure 11: Effect of mGluS PAM treatment on % Freezing in (a) Delay and (b) 
Trace Extinction in adult rats treated with MAM on E17. 
Effect of 1 mg/kg mGlu5 PAM on percentage freezing in (a) delay and (b) trace fear 
extinction in MAM E17 treated rats. Data are presented as mean ± standard error of 
the mean (n = 12 for all groups). 
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4.4 Discussion 
In the above studies we have observed that maternal treatment with 
methylazoxymethanol acetate (MAM) results in emotional learning and memory 
deficits as shown by impairments in delay and trace fear conditioning but to varying 
degrees and variability. MAM treated rats in study 1 had impairments in trace 
conditioning and delay and trace extinction but study 2 only showed deficits in 
trace contextual freezing and treatment with the mGluS positive allosteric 
modulator did not ameliorate these deficits. There was no effect of MAM 
treatment on body weight and MAM treatment produced a reduction in juvenile 
brain weight. 
Esclassan et al., (2009) have previously shown that neurotoxic lesions of the whole 
hippocampus impair both contextual and tone freezing in both trace and delay 
conditioned rats. They went on to assess the dorsal and ventral hippocampal 
contributions to the deficit. Ventral and dorsal inactivation abolished contextual 
freezing in the trace group but had no effect in the delay conditioned group. With 
regards to extinction, dorsal hippocampus inactivation impaired trace fear only 
whereas ventral inactivation impaired both delay and trace fear. They suggest that 
the ventral and dorsal parts of the hippocampus compute different aspects of trace 
conditioning with the ventral being involved in fear and anxiety processes and the 
dorsal involved more with the temporal and contextual aspects. As the MAM-
treated rats in study 1 showed impairments in trace conditioning and both delay 
and trace fear extinction, and those in study 2 showed impairments in trace 
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contextual freezing, this supports a hippocampal deficit in the model, be it variable. 
This is further supported by data that show that there is reduced synaptic 
transmission and innervations in the dorsal but not the ventral hippocampus in 
MAM treated rats (Sanderson et 01., 2012) whereas lodge and Grace (2007) 
demonstrate that adult MAM rats display a significantly greater number of 
spontaneously firing ventral tegmental DA neurons. They postulate this is due ~ o o a 
consequence of excessive ventral hippocampal activity as inactivation of this area 
completely reversed the elevated DA neuron population activity. 
The MAM E17 model has also previously been shown to produce deficits in various 
versions of fear conditioning. Shors et 01., (2002) injected adult rats with MAM for 7 
days to reduce hippocampal neurogenesis by approximately 80% (Shors et 01., 
2001; Shors et 01., 2002). Consequently, they reported deficits in two hippocampus-
dependent tasks: trace-eyeblink and trace-fear conditioning, impairments that were 
reduced upon recovery of neurogenesis. Another group used the MAM E17 model 
in a classic 1 trial delay fear conditioning task across successive days. They found 
increased asymptotic freezing to context and cue in the MAM-treated animals 
compared to controls. They suggest the treatment on E17 may result in a relative 
increase in the efficacy of the amygdala due to compensatory mechanisms that 
could lead to the observed increase in fear conditioning (Tinsley et 01., 2003). This is 
further supported by our delay data. The same group also subjected the MAM-
treated rats to delay or trace variants of fear conditioning. Contextual- and tone-
elicited freezing were comparably high for all animals 24 hr after training. However, 
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they found that MAM rats extinguished more rapidly to the context than the 
controls in the delay paradigm whereas we found this was the case for trace not 
delay conditioning. Both data suggest that the context-fear association is weaker in 
MAM rats. Furthermore, 24 hrs after extinction, they found MAM rats showed 
evidence of impaired retention of extinction, which is consistent with new-rule-
learning deficits observed in schizophrenia patients and prefrontal cortex l e s i o ~ e d d
subjects (Davoli et al., 2003). These findings further suggest that behavioural 
regulation by the hippocampus and prefrontal cortex is abnormal in MAM rats, 
which results in contextual stimuli being rendered less salient and new-rule learning 
impairment. This is further supported by our findings in Chapter 2 showing that 
treating rats prenatally with MAM disrupts limbic and cortical development 
resulting in an adult phenotype reminiscent of schizophrenia. 
Holt et al., (2009) examined fear and extinction learning and memory in patients 
with schizophrenia by measuring skin conductance responses (SCRs) using a 2 day 
Pavlovian fear conditioning and extinction paradigm (Milad et al., 2005). They found 
that both healthy control subjects and schizophrenic patients were able to 
successfully acquire and extinguish conditioned fear responses. Twenty-four hours 
following successful extinction, healthy control subjects exhibited lower SCRs 
compared to the schizophrenic patients who showed an excessive fear response 
(high SCRs), thus failing to demonstrate appropriate context gating of extinction 
memory retrieval. The same group also found that the extinction memory 
impairment found was associated with ventral medial PFC dysfunction (Holt et al., 
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2012) by measuring fear and extinction learning and memory while simultaneously 
collecting functional magnetic resonance imaging (fMRI) data. Interestingly, a 
substantial proportion of the patient group (43%) were also excluded from the 
study as they were deemed non-responders. Other studies of aversive conditioning 
in schizophrenia have also produced mixed results, (Sears et al., 2000; Jensen et al., 
2008; Kosmidis et al., 1999; Hofer et al., 2001; Howe et al., 1958). Th.ese 
inconsistencies might be due in part heterogeneity within patient samples. Some 
studies have found that one-third to one-half of the patients exhibited no learning 
at all, whereas the remaining patients showed normal acquisition of aversive 
conditioning (Kosmidis et al., 1999; Howe et al., 1958). These findings are 
consistent with evidence for the existence of a subpopulation of patients with 
schizophrenia with abnormally low or absent autonomic responses to salient stimuli 
(Ohman et al., 1981). This could also account for the variability seen in our current 
data where maybe not all offspring were equally affected by MAM treatment 
resulting in the inconsistencies between the studies. 
The ultimate aim of the present study was to further evaluate the validity of the 
prenatal MAM treatment as a neurodevelopmental model for the emotional 
learning and memory behavioural changes observed in schizophrenia. Although we 
did detect deficits in both delay and trace fear conditioning paradigms, these were 
highly inconsistent despite the consistent microencephaly observed in the MAM 17 
animals. This lack of consistency observed in the present investigation leads us to 
the general conclusion that the prenatal MAM treatment may have validity as a 
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behavioural model for deficits related to hippocampal abnormalities seen in 
schizophrenia but an alternative hippocampal dependent assay may be more 
appropriate. 
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Chapter 5: General Discussion 
5.1 Introduction 
The main aim of this thesis was to perform a behavioural characterisation of the 
Methylazoxymethanol Acetate E17 neurodevelopmental model of schizophrenia in 
rats. One of the major challenges in schizophrenia-related drug discovery is to find 
an appropriate animal model of the illness so that novel hypotheses can be tested 
at the basic science level. As more knowledge of the pathophysiology of 
schizophrenia accrues, it is essential that appropriate animal models of the illness 
be developed that have better translational value. Secondly, the model was utilised 
to elucidate the pro-cognitive effects of an mGlu5 positive allosteric modulator in 
assays of cognitive flexibility and learning and memory to determine the use of the 
model as a tool for drug discovery. The purpose of this chapter is to review the 
results of the previous chapters and discuss the implications of the combined 
findings with regards to the aims of the thesis. 
Chapter 1 provides a general overview of schizophrenia, hypotheses, treatment and 
how the disorder can be modelled in animals. In its simplest form the 
neurodevelopmental hypothesis posits that schizophrenia is the behavioural 
outcome of an aberration in neurodevelopmental processes that begins long before 
the onset of clinical symptoms and is caused by a combination of environmental 
and genetic factors (Rapoport et 01., 2005). There are several potential difficulties 
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associated with modelling schizophrenia in animals, including the standard caveat 
of reproducing what is generally perceived to be a cognitive disorder in less 
cognitively developed animals. More specifically, heterogeneity in clinical 
symptoms, course of the disorder and potential causative factors represent 
significant obstacles to model building. Patients typically experience a combination 
of symptoms, often divided into positive (e.g., hallucinations, delusions, thought 
disorganizations), negative (e.g., loss of motivation, affective blunting, alogia, social 
withdrawal) and cognitive (e.g., deficits in attention, memory and executive 
functions) (Andreasen 1995). Accordingly, current animal models of schizophrenia 
are not intended to serve as the complete animal equivalent of the human disorder. 
Rather, they are often designed to test specific causative or mechanistic hypotheses 
regarding schizophrenia. The models can be validated on the basis of how well their 
performance in a given test predicts the performance of humans with schizophrenia 
and/or on whether the model provides a sound theoretical rationale. 
5.2 Summary of findings 
The first part of this thesis (Chapter 2) investigated the basic behavioural profile of 
the MAM E17 model in different strains, sexes and ages. The data show that 
maternal treatment with MAM on E17 leads to behavioural, neuroanatomical and 
pharmacological alterations in the resultant male offspring of Sprague Dawley CD 
rats. These changes include decreased brain weights, PPI deficits and 
hypersensitivity to MK-801 measured by changes in locomotor activity that have 
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translational relevance to some of the core symptoms seen in schizophrenia. 
Furthermore, the absence of these deficits pre-puberty in the same rats indicates 
that this model may also replicate the adolescent onset of psychosis seen in this 
human disorder. However this study suggests that these changes are strain and sex 
specific, suggesting a genetic component could be involved, since they do not 
occur in male LH or female CD rats under identical experimental conditions. 
To investigate any potential cognitive deficits observed in the model, the second 
and third part of the thesis involved looking at the performance of MAM E17 
treated rats in assays of behavioural flexibility and learning and memory. The utility 
of the model to investigate the effects of a potential pro-cognitive compound for 
drug discovery in these tasks were also determined. The studies in chapter 3 
consistently demonstrated that maternal treatment with MAM on E17 results in 
deficits in cognitive flexibility as measured by the rodent spatial reversal learning 
task. The studies also show that the novel mGlu5 PAM LSN2814617 reverses these 
deficits. In the fear conditioning chapter, we have observed that maternal 
treatment with methylazoxymethanol acetate (MAM) results in emotional learning 
and memory deficits as shown by impairments in delay and trace fear conditioning 
but to varying degrees and variability. In the first study we saw impairments in trace 
conditioning and in delay and trace extinction but the second only showed deficits 
in trace contextual freezing with no change in extinction. Treatment with the mGlu5 
PAM in this case had no effect on the deficits observed. 
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Overall, the observations from this study and those of other groups indicate that a 
disturbance in neurodevelopment induced by MAM administration on E17 leads to 
several behavioural and neuroanatomical changes similar to the core 
pathophysiological changes characteristic of schizophrenia (Featherstone et 01., 
2007; Rizos et al. 2007; Styner et 01., 2005). These include reduction in tissue 
volume, increased neuronal density and ventricle size, and disorganisation of the 
hippocampus. Deficits are also seen in several behavioural measures that emerge 
after puberty. These include deficits in PPI, hypersensitivity to NMDA receptor 
antagonists in locomotor activity and deficits in cognitive flexibility. We also confirm 
that positive modulation of mGlu5 receptors may have beneficial effects in the 
treatment of certain cognitive impairments associated with schizophrenia. Further 
studies are needed to test the mGlu5 effects in other memory and executive 
functions, such as working memory. The present findings also show face and 
construct validity and but also present an opportunity for the predictive validity of 
the MAM E17 model for remediating specific cognitive deficits in schizophrenia to 
be tested. However, our work makes it clear that care must be exercised in the 
selection of rat strain and gender to be used since male LH rats are essentially 
resistant to MAM E17 treatment. 
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5.3 Variability 
Although the summary of the findings presented in this thesis paints a very positive 
picture with regards to the model, this is not always the case. Table 1 displays all 
the different MAM batches that have been generated at Lilly since I started my PhD 
and the different assays used to test them. A yes indicates whether a deficit is seen 
in a particular assay. The table shows, that a deficit in an assay in one particular 
batch may not mean that the same deficit will be present in another batch. 
M.tA 
M·tA 
M.gA 
TOTAL . 22/23 5/5 5/5 4/6 2/5 3/11 4/8 0/1 2/3 2/2 
Figure 1: Table displaying the different MAM batches generated at Lilly and the 
different assays used to test them. A yes indicates a deficit. 
This variability could actually be that the model actually 'models' the 
heterogeneous nature of schizophrenia very well. Taking our results in fear 
conditioning as an example where we found deficits in extinction in the first study 
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but not the second. Studies of aversive conditioning in schizophrenia patients have 
also produced mixed results where some have found deficits (Jensen et 01./ 2008, 
Kosmidis et 01./ 1999, Hofer et 01./ 2001) and others no change compared to control 
subjects (Kosmidis et 01./ 1999, Howe et 01./ 1958). However, variability within a 
preclinical model is not conducive to drug discovery. 
Another reason for the variability seen in the MAM El7 model may be because 
specific litters are affected more by MAM treatment than others. Unfortunately this 
cannot be directly controlled as it is the DAM that is treated by MAM and not the 
offspring. However, this could be accounted for any future experiments in the 
experimental design and statistical analysis. As it is the DAM that is the actual 
experimental unit and the pups are the observational units, we need to take into 
account the nesting structure - this is because the average correlation between 
variables measured on pups from the same litter could be higher than the average 
correlation between variables measured on pups from different litters. Spatz and 
Laquer., (1986) have stated that a striking feature of chemically induced 
microencephaly (by MAM) was its uniformity among littermates. Standard 
statistical tests rely heavily on the assumption of independence of the observations. 
If this assumption is violated (as is usually the case in nested data) the estimates of 
the standard errors of conventional statistical tests are much too small and this can 
result in false positives. 
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Variability in preclinical experiments is not specific to this model. A commentary by 
Peers et al., (2012) highlight that a major factor in the high clinical failure rates in 
pharmaceutical research and development is due to insufficient robustness in 
preclinical studies. Although not specific to schizophrenia or even psychiatry, one 
example they cite is from Begley and Ellis., (2012) who reported that only 6 out of 
53 landmark studies in oncology were reproducible. They also cite an investigation 
at Bayer (Prinz et al., 2011) where they found that around two thirds of studies 
were stopped due to lack of reproducibility seen in preclinical research. Indeed, one 
the factors suggested by Peers et al., (2012) to contribute to the lack of 
reproducibility is the inadequate use of statistics. They state that statistical issues 
such as variability and bias and their impact their impact on design, analysis and 
interpretation of scientific experiments are often misunderstood. 
Given the high variability seen in our findings, we contacted other laboratories who 
either work on the model or have done previously, and found that all found the 
same level of variability in their data and many cited this as a reason for not taking 
the model further. However if you search the current MAM E17 literature you will 
find no mention of this variability. Begley and Ellis., (2012) hypothesise that lito 
obtain funding, a job, promotion or tenure, researchers need a strong publication 
record, often including a first-authored high-impact journal. Journal editors, 
reviewers and grant-review committees often look for a scientific finding that is 
simple and clear and complete - a 'perfect' story. It is therefore tempting for 
investigators to submit selected data sets for publication, or even to massage data 
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to fit the underlying hypothesis." Drug development relies heavily on the literature, 
especially with regards to new targets, biology and assays and as Begley and Ellis 
rightly state, there are no perfect stories in biology. In fact, gaps in stories can 
provide opportunities for further research and if this is not the case, not disclosing 
this so called 'negative data' often results in another research group pursuing a 
similar, wasting time and money in uninformed redundancy. I think this is an issue 
that we have generally have in the science community and we need to be working 
more on sharing all types of data, not just those data that are deemed positive. 
5.4 Future Work 
As mentioned previously, accounting for litter effects in the experimental design 
and analysis will be an important aspect of any future work but could we use the 
litter effects to our advantage. Could we use it to assess which litters would have 
the largest deficits and so only use those litters in experiments thereby potentially 
erasing high variability of findings? We have just undertaken a study where MAM 
E17 rats are assessed, consecutively, in several assays, including PPI, reversal 
learning, fear conditioning, electrophysiology and then the brains extracted for 
neuropathology. Assessing the same animals through several assays will allow 
performance of a correlation analysis to assess if a particular rat or litter has a 
deficit in one assay, for example PPI, would that mean it will also have a deficit in 
other assays. Running a large number of animals through each assay will also allow 
assessment of any within litter correlations. If any correlations arise, then 
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potentially, one particular assay could be utilised as a 'biomarker' to allow 
incorporation of only those animals with a MAM deficit in any further experiments. 
NEWMEDS (Novel Methods leading to New Medications in Depression and 
Schizophrenia) is an international consortium of scientists that has launched one of 
the largest ever research academic-industry collaboration projects to find new 
methods for the development of drugs for schizophrenia and depression. One of 
the aims of the initiative is to assess pharmacological, neurodevelopmental and 
genetic models of schizophrenia, and the MAM E17 model has been chosen to be 
one of these. MAM treated animals will be generated at two sites, Charles River in 
the UK and Charles River in the US and then assessed in a wide range of assays by 
many of the different sites to assess reproducibility in the model as well as in the 
assays being tested. 
5.6 Conclusion 
To conclude, our data suggests that maternal treatment with MAM on embryonic 
day 17 leads to persistent alterations in the adult offspring of CD rats that are 
relevant for modelling aspects of schizophrenia and could be important for 
discovery of novel therapeutic drugs for the treatment of schizophrenia. However, 
revised methods for study design and statistical analysis are crucial to avoid 
misinterpretation of findings. "Negative" observations and conclusions, based on 
rigorous experimentation and thorough documentation, should be published in 
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order for them to be discussed, confirmed or refuted by others. This may also 
reveal fundamental flaws and obstacles in commonly used methods, ultimately 
leading to improvements in experimental designs. 
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